Podcasts about Molecular genetics

BUFFALO, NY — May 19, 2026 — A new #research paper was #published in Volume 18 of Aging-US on May 5, 2026, titled “Methylene blue protects hair follicle stem cells from oxidative and metabolic stress to enhance hair regeneration.” The study was led by first author Kavitha Sadashivaiah and corresponding author Kan Cao from the Department of Cell Biology and Molecular Genetics at the University of Maryland, College Park. In this study, the authors investigated how methylene blue (MB), a long-established mitochondrial-targeted antioxidant, affects human hair follicle stem cells (HFSCs) under conditions of oxidative and metabolic stress. Hair follicle stem cells are essential for maintaining hair growth and regeneration, but aging, ultraviolet radiation, oxidative stress, and metabolic dysfunction can impair their regenerative capacity and contribute to hair thinning and scalp aging. Using cultured human HFSCs, the researchers found that methylene blue significantly enhanced stem cell proliferation and viability while reducing intracellular reactive oxygen species (ROS). Importantly, MB also increased activation of β-catenin signaling, a central pathway involved in hair follicle regeneration, stem cell maintenance, and wound repair. Functional scratch-assay experiments further demonstrated that MB accelerated wound closure and regenerative activity in HFSC cultures. The study also explored how methylene blue interacts with other compounds commonly associated with scalp or hair health. While antioxidant vitamins A and C improved oxidative stress scavenging, they unexpectedly reduced MB-induced β-catenin activation when used in combination. In contrast, minoxidil—the widely used hair growth stimulant—worked synergistically with MB to further enhance β-catenin signaling and improve HFSC viability. “Overall, these findings identify methylene blue as a multifunctional therapeutic candidate that reduces oxidative and metabolic stress while supporting HFSC–mediated hair regeneration.” Another major focus of the paper involved glucagon-like peptide-1 receptor agonists (GLP-1 RAs), medications increasingly used for diabetes and weight management. Recent clinical observations have suggested that some patients receiving GLP-1 RA therapy may experience hair thinning or hair loss. The authors demonstrated that increasing GLP-1 RA concentrations caused dose-dependent reductions in HFSC viability in vitro. However, pretreatment with methylene blue substantially protected the stem cells from GLP-1 RA–associated metabolic stress and premature cell death. Beyond stem cell protection, the paper discusses methylene blue's broader potential role in scalp health. Because MB absorbs ultraviolet radiation and has previously demonstrated protective effects against UV-induced DNA damage in skin cells, the authors propose that it may help shield the scalp microenvironment from oxidative injury while supporting regenerative signaling pathways important for hair maintenance. The study also highlights MB's possible antimicrobial properties and its potential influence on scalp microbiome balance. Importantly, the authors emphasize that the findings are based on in vitro cellular models and that further in vivo studies will be necessary before clinical applications can be established. Additional research will be required to define appropriate dosing, pharmacokinetics, long-term safety, and therapeutic efficacy in living systems. Overall, this study identifies methylene blue as a potentially multifunctional therapeutic candidate for supporting hair follicle stem cell health under conditions of oxidative, metabolic, and pharmacologic stress. By combining antioxidant activity with activation of regenerative β-catenin signaling, MB may represent a promising future strategy for protecting scalp health, enhancing hair regeneration, and improving the resilience of aging hair follicle stem cells. DOI - https://doi.org/10.18632/aging.206376

I am back from my trip to Florence, and am covered in history. It is impossible to go to Florence and not be. Unless you are a college student who is doing study abroad and only know about Rafael, Donatello, Michelangelo, and Leonardo from the Teenage Mutant Ninja Turtles cartoon and movie. It was kind of crazy to be able to walk around and casually see works of art from the 1300s. It is easy to say things like “Florence is the birthplace of the Renaissance,” but when you see it in person, it makes quite the impression. Staring at a Giotti or a Botticelli or a Caravaggio leaves a mark. Being able to walk streets or sit in piazzas, thinking about the centuries of footsteps that preceded puts one life in a certain perspective. Speaking of perspective, I don't know if anything quite prepares you for standing in front of David looming over the crowds. Perfectly proportionate but on a whole other scale.  It wasn't just the past that was impressive, but the present as well. The artists who were working on the streets, showing their beautiful works in front of other beautiful works while people walked by in beautiful fashion. Beauty upon beauty upon beauty. While there, I even had the chance to take in a Mark Rothko exhibit, who interestingly enough was influenced by Renaissance art and visited Florence many times.  So much art, so many museums, so many ways to tell the story of this history.  This is why it is good timing to have Will Humphrey of the agency Sugar Creative on Experience by Design. Will started out as a fine artist, having his work exhibited as any artist would. His education combines degrees in Graphic Design and Communication as well as Molecular Genetics. Today he is the Director of Creative and Innovation at Sugar. At Sugar, he is part of a creative force that combines augmented reality, virtual reality, storytelling, and history together to bring the past into the present.  We talk about Sugar's project on the American Revolution that will allow users to experience pivotal historical moments through interactive experiences. Will shared the inspiration he received from his grandfather, who developed anti-aircraft balloons during the Battle of Britain. We share our appreciation of video games, especially those with historical features and lessons, such as Assassin's Creed Valhalla. Will talks about how they are working with Ubisoft to combine gaming and history to make for immersive learning experiences.  Will shares insights from his work on geolocated experiences, highlighting the value of immersing oneself in a set of ideas and understanding the physical and historical context of a place. We also discussed how physical transformations, such as landfill in Boston, affect our understanding of history and the importance of considering the nature of a space in designing experiences.   We cover a lot of ground in this chat, which is about as much ground as I covered walking around Florence and its many museums. Will Humphrey on LinkedIn: https://www.linkedin.com/in/willhumphreyuk/ Sugar Creative: https://www.sugar.agency/

In this week's episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Tania Nayak Kamphaus, PhD, Associate VP of Science Partnerships at the Foundation for the National Institutes of Health (FNIH). In December 2025, the FDA qualified bone density DXA scans as the first surrogate endpoint for bone fractures in clinical trials of anti-osteoporosis drugs in post-menopausal women at risk for osteoporosis fracture. The surrogate endpoint will allow for measuring change in bone mineral density, rather than fracture occurrence, promising to speed the development of new drugs to treat osteoporosis. The decision was based on FNIH's request for qualification through the work of the FNIH Biomarkers Consortium. Dr. Kamphaus leads patient engagement at FNIH and oversees programs across its Metabolic Disorders, Inflammation and Immunity and Women's Health portfolios. She develops multi-stakeholder public-private partnerships involving NIH, FDA, non-profits and life sciences companies, and oversees target validation efforts within the Accelerating Medicines Partnership (AMP), as well as biomarker qualification initiatives in areas including preeclampsia and osteoporosis. Dr. Kamphaus conducted her postdoctoral fellowship at Columbia University and has a PhD in Molecular Genetics from The Ohio State University. Tune in to hear Dr. Kamphaus discuss the FDA's decision on the new surrogate endpoint for bone fractures, the science behind the biomarker and the real-world impact it will have on the speed and cost of osteoporosis drug development.   For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Dr Deb Muth 00:03Well, welcome back to Let’s Talk Wellness Now. I am your host, Dr. Deb. And what is the most talked-about peptides in functional medicine? aren’t actually FDA approved. Not because they don’t work, but because no one’s funded the research to prove it yet. The truth is, some of the compounds that dominate wellness forums, BPC-157, TB-500, thymosin beta-4, epitalin, occupy a fascinating space between breakthrough science and unregulated experimentation. In today’s episode, we’re stepping into that grey zone, the world of investigational peptides, to separate mechanism from marketing. I’m going to walk you through the science that actually shows and where it stops, how to evaluate claims when human data don’t yet exist, and the quality, purity, and safety red flags that you need to recognise. Dr Deb Muth 01:06I created it in a previous episode, so go check that one out. And why honesty is the most important prescription in peptide medicine. If you’ve ever wondered whether these research-only peptides are the frontier of healing or the next functional medicine fad, this episode is for you. So grab your cup of tea or coffee, get comfortable, and let’s talk about what it really means to use peptides that are promising but still under investigation. So we’re going to break just for a second here and have a word from our sponsor. It is because of them that we stay on the air. So thank you for this. And we will be right back. Did you know sweating can literally heal your cells? Infrared saunas don’t just relax you. They detox your body, balance hormones, and boost mitochondrial energy. I’m obsessed with my Health Tech sauna. And right now, you can save $500 with my code at healthtechhealth.com slash dr-muth-req-25. Dr. Deb Muth 02:15All right, guys, welcome back. Let’s dive into investigational peptides, the evidence gap. So the following peptides we’re about ready to discuss are extensively in integrative, functional, and regenerative medicine circles. They may have intriguing mechanisms and promising preclinical data. However, they lack FDA approval, and the evidence quality varies dramatically. from interesting preliminary research to essentially no human data at all. And this distinction is really critical for maintaining scientific integrity. So let’s talk about immune-modulating peptides. There’s thymus and alpha-1, and this is an international story on the thymic peptides. Thymusin alpha-1, known as TA1, is marketed internationally as zidaxin. Dr. Deb Muth 03:16It’s a 28-amino acid polypeptide originally isolated from thymusin fraction 5, which was extracted from bovine thymus tissue. Modern production uses synthetic peptide synthesis. The thymus gland is located behind the sternum and is the primary site for T cell maturation, and thymic peptides like TA1 play roles in human system development and regulation. Now, I love thymus peptides. I love thymus glandular products. I’ve used thymus glandular products for decades. Ground-up animal thymus gland is basically what it is. There are a couple of different supplement companies that I’ve used over the years that are amazing with this. And they do a fantastic job, and they really do help to support the immune system. So when thymus peptides came out, it was really exciting because it took the whole idea of thymus support to a new level. Dr. Deb Muth 04:17The mechanism actually behind the thymus in alpha-1 is complex and involves multiple aspects of immune function. At the cellular level, TA1 enhances T cell maturation and differentiation, particularly the development of helper T cells and cytotoxic T cells. It modulates T cell receptor expression and can influence the balance between Th1 cell-mediated immunity and Th2 humoral immunity responses. And it also enhances the natural killer cell activity and modulates dendritic cell function, which are critical for antigen presentation. and initiation of adaptive immune responses. And on the cytokine level, TA1 influences production of interleukin-2, IL-2, interferon gamma, IFN-γ, and interleukin-10, IL-10. Dr. Deb Muth 05:19These create immune modulatory rather than simple immune stimulatory effects. This is a very important distinction because TA1 appears to help balance the immune system rather than simply ramping this up, which theoretically makes it safer in conditions where immune overstimulation would be a problem, such as an autoimmune disease. Hashimoto’s, autoimmune, lupus, Sjogren’s, any of those autoimmune diseases, we don’t want to overstimulate their immune system. So you want to use a product like this that’s non-stimulating. Now, the regulatory status on TA1 is geographically variable and represents one of the challenges in discussing this peptide with patients. It is not FDA-approved in the United States. However, it is approved in several other countries for specific conditions. Dr. Deb Muth 06:19In Italy, it’s approved for the treatment of chronic hepatitis B and hepatitis C. In China, it’s approved for chronic hepatitis B and adjunct immune compromised patients receiving vaccinations or suffering from certain infections. It has an orphan drug designation in the United States for certain cancer indications, but its designation does not constitute approval. It simply provides regulatory incentives for further development. So the evidence base for thymosin alpha-1 is substantial in some areas but comes primarily from non-US populations and research groups, which creates challenges in evaluating quality and generalizable information. So in hepatitis B and C, multiple clinical trials, many conducted in China and Italy, have examined TA1 as an adjunct to antiviral therapy. Dr. Deb Muth 07:21A meta-analysis by Wu and colleagues published in the Journal of Viral Hepatitis in 2013 examined 23 randomized controlled trials, including over 2,000 patients with chronic hepatitis B. The analysis found that combining TA1 with nucleoside analogs like LAMVDUDE or an and TCAVAR improved the hepatitis antigen seroconversion rates by HBV DNA clearance compared to its nucleoside analogs alone. And the effect sizes were modest but statistically significant, with the HBE-AG seroconversion rates improving from about 24% with antivirals alone to 38% in combined therapy. Now in hepatitis C, early trials before the development of direct-acting antivirals showed that TA1 combined with interferon alpha improved sustained virological responses, and compared to interferon alpha, Dr. Deb Muth 08:30Furon alone, particularly in difficult-to-treat populations like those with a genotype one or a high viral load. However, the advent of highly effective direct acting antivirals that achieve SRV rates, sorry, SVR rates exceeding 95%, the role of TA1 in hepatitis C has become less clear. Now in sepsis and critical illness, more recent interest has focused on TA1 in severe cases of sepsis and septic shock. Ren and colleagues published a systematic review and meta-analysis in the Frontiers of Immunology in 2022, analyzing 18 randomized controlled trials, including 1787 patients with severe sepsis or septic shock the pooled analysis showed that ta1 administration was associated with reduced 28-day mortality relative risk at 0.70 meaning a 30 reduction in mortality compared to the standard care alone and the effect appeared Dr. Deb Muth 09:39most pronounced in patients with sepsis-induced immunosuppression measured by HLA-DR expression in monocytes. Now, this is amazing because going forward, we’re going to talk about something that’s commonly known as cytokine storm. Now, cytokine storm really became apparent since 2020 with the viral infection that we’re dealing with in the world today. But they were already looking at this kind of cytokine storm produced by sepsis or sepsis-induced immunosuppression. And it triggered this hyperinflammatory response called the cytokine storm. And many patients who survived the initial phase of the immune suppressed stata, characterized by a T cell exhaustion, reduced antigen presentation, and increased susceptibility to secondary infections. Thymusin alpha-1, TA1, may help restore this immune competence in this phase. However, it’s important to note that patient selection and timing are critical. Dr. Deb Muth 10:43Giving this immune stimulant during a hyperinflammatory phase could theoretically worsen outcomes. So you don’t want to give it to them while they’re in the flare up or the sepsis or the infection, but given to them during the immunosuppression phase afterwards might be beneficial. Now there is also some cancer immunotherapy that we see with TA1 and has been studied as an adjunct in cancer treatment with the hypothesis that it could enhance immune surveillance and response to tumors. And a comprehensive review of Garci and colleagues published in Expert Opinion on Biological Therapy in 2007 examined multiple trials in melanoma, lung cancer, hepatocellular carcinoma, and other malignancies. And the results were mixed. Some trials showed improvement in the immune parameters, increased CD4 in T-cells. improved lymphocyte proliferation responses and some actually showed trends toward improved progression free survival but overall survival benefits were inconsistent and the heterogeneity of the cancer types treatment protocols and outcome measures makes a definitive conclusion difficult as a vaccine adjunct several studies particularly from china have examined ta1 as an adjunct to enhance vaccine responses Dr. Deb Muth 12:11in immune-compromised populations, including the elderly, dialysis patients, and transplant recipients. The rationale is sound. These populations often mount suboptimal antibody responses to vaccines, and TA1’s immune-enhancing effects might improve protection. There are small trials. They have shown improvement in seroconversion rates of hepatitis B vaccines and influenza vaccine in these populations. And though large-scale confirmatory studies are limited, there is a possibility here. Now, on their safety profile, one of the appealing aspects of thymusin alpha-A TA1 is that it’s apparently favorable safety profile in clinical trials. There are some injection site reactions with a little redness, a mild discomfort, and most commonly reported adverse effects. is that their severe adverse events attributable to TA1 have been rare in published trials. However, comprehensive long-term safety data are limited Dr. Deb Muth 13:13And theoretically, concern exists that immune modulation could potentially trigger or exasperate autoimmune conditions in susceptible individuals. Though this hasn’t been clearly demonstrated in clinical trials, integrative medicine considerations for integrative practitioners concerning the thymus and alpha-1, several factors require careful thought. First, sourcing and quality control are critical concerns. Since it’s not FDA approved, TA1 available in the United States typically will come from a compounding pharmacy or an international supplier with variable quality assurance. And pharmaceutical grade product with certificates of analysis showing purity, sterility, and endotoxin testing is essential, but it is readily available from many of these companies. Second, patient selection matters immensely. TA1 should be considered in complex cases where conventional approaches have been insufficient, such as chronic viral infections not responding adequately Dr. Deb Muth 14:21to standard antivirals, post-viral syndromes with evidence of immune dysfunction, cancer patients with immune suppression in consultation with oncology, and it should generally be avoided in active autoimmune disease unless there’s a compelling rationale and close monitoring. Now, TA1 is not a standalone therapy. In cases of chronic viral infection, Comprehensive immune support includes addressing nutritional deficiencies, optimizing vitamin D levels to be between 50 and 80, adequate zinc, selenium, and vitamin A, optimizing gut health since 80% of our immune function is in the gut, you need to optimize gut function. Managing stress from the HPA access dysfunction, chronic cortisol elevation, suppression, and immunity, ensuring adequate sleep, immune memory consolidations during sleep, addressing any metabolic dysfunction, insulin resistance, repairs in the immune function, and the bottom line on thymus and alpha-1 is Dr. Deb Muth 15:26is that it represents legitimate medicine in other countries with a substantial evidence base in specific contexts, but it remains experimental in the U.S., and practitioners using it should provide comprehensive, informed consent about its regulatory status, evidence quality, and source verification. while ensuring it’s part of comprehensive protocols. It is not a magic bullet. And again, what you’re gonna hear me say quite often here is that many of these peptides should be used in conjunction with something else. They should not be used alone. And can peptides be stacked? The answer is yes, they can. So if somebody has an insulin resistance, or a metabolic dysfunction, they can tier TA1 with a GLP-1 like terzepatide or semiglutide. That is not a problem to do that. You need to just work with a practitioner that understands how to do that effectively. So let’s look at BPC-157. Dr. Deb Muth 16:26This is a phenomenon I love BPC-157. Let’s separate it from marketing to actual mechanism of actions here. So BPC-157 stands for Body Protection Compound 157. It is a chain of 15 amino acids that are described as a partial sequence of body protection compound, a protein found in human gastric juice. It has become one of the most hyped peptides in regenerative medicine inside the athletic performance and biohacking communities with claims ranging from healing tendons and ligaments to repairing gut lining or reversing organ damage. The challenge is separating the legitimate mechanisms of science from the marketing hype. The proposed mechanism of BPC-157 are biologically plausible and intriguing. The research suggests that it may influence several growth factor pathways, including vascular endothelial growth factor, VEGF, which promotes new blood vessel formation and has improved better supply of blood flow to injured tissues, theoretically accelerating healing. Dr. Deb Muth 17:40It may also affect fibrous blast growth factor, FGF, and transforming growth factor beta, TGF beta pathways. both involved in tissue repair and remodeling. And some studies actually suggest that BPC-157 modulates inflammatory cascades, potentially reducing excessive inflammation while promoting the resolution phase that allows tissue rebuilding. Now I want to talk just a few moments here about these different tests that we’re talking about tgf beta veg f for those of you who are in our mold world you are very familiar with these uh lab tests we do this to see if you have a mold exposure what’s happening to your body and it’s been very challenging to try to heal this part of the mold illness and manipulate these VEGFs and TGF betas. And so with the fact that BPC helps us modulate this inflammatory cascade, BPC can be very helpful in the world of mold or mycotoxin illness in repairing those parts of the body that have been damaged by the mycotoxins. Dr. Deb Muth 18:48Now there is animal research on BPC-157. It is extensive and primarily from a research group led by pre-drag, oh, I can never say these names, Cyrek at the University of Zagreb in Croatia. Published studies in animal models have shown accelerated healing in a remarkable variety of injury types. A 2011 paper by Chang and colleagues in the Journal of Applied Physiology demonstrated that BPC-157 improved therapy tendon healing in rats with Achilles tendon injuries, and the treated rats showed increased tendon outgrowth, better cell survival in the injured area, enhanced cell migration to the injury site, and improved biochemical strength of the healed tendon compared to controls. Multiple other animal studies have shown similar promising effects. Ligament tears, healing faster in rabbits, muscle damage recovering more quickly in rodent models, gastric ulcers healing in rats given experimental induced ulcerations, inflammatory bowel lesions improving in mouse models of colitis, and even bone to tendon healing showing enhancement in animal studies. Dr. Deb Muth 20:02The breadth of injury types showing benefit in preclinical models explains the enthusiasm of this peptide. However, this is critical. These animal studies, primarily in rodents and rabbits, animal models of injury healing don’t reliably translate to human clinical outcomes. And the doses used in these animal studies when converted to human equivalent doses vary widely. And optimal human dosing is completely unknown at this point. it is all considered experimental and perhaps most importantly there are essentially no peer-reviewed controlled clinical trials in human published in humans published in major medical journals in a 2001 review of arthroscopy and the journal of arthroscopic and related surgery specifically examined in the evidence of bpc 157 and other peptides in musculoskeletal medicine The authors concluded bluntly that BPC-157 lacks evidence from randomized controlled trials and has an unknown safety profile in humans. Dr. Deb Muth 21:09 They emphasized that the jump from animal data to recommending peptides for humans use bypasses the fundamental requirement for Phase I safety studies, Phase II dose-finding studies, and Phase III efficacy trials that would establish whether BPC-157 actually works in humans and whether or not it’s safe. The absence of human safety data is particularly concerning given BPC-157’s proposed mechanisms. Peptides that influence growth factor signaling and angiogenesis could theoretically have off-target effects. Uncontrolled angiogenesis, for instance, is a hallmark of cancer progression. Tumors require blood vessel formation to grow beyond a certain size. And while there’s no evidence that BPC 157 promotes cancer, The complete absence of long term human safety studies means we simply don’t know. This isn’t fear mongering. It’s acknowledging uncertainty and uncertainty exists and understanding that if you’re choosing to use peptides like BPC 157, you are doing it in an experimental model. Dr. Deb Muth 22:17We’re experimenting with the doses that are being used. And there is potential for it to cause cancer cells in your body to grow. And you need to be aware of this and understand the risks that you’re taking when you’re using an investigational or off label use peptide. Now, quality control issues with BPC also exist. It’s not FDA approved for any indication in the US. It’s not approved in any major regulatory jurisdiction worldwide. It’s marketed as a research chemical explicitly to bypass FDA oversight. And commercial sources selling BPC-157 range from compounding pharmacies, which have some quality standards but are not FDA inspected. You can take that for what you want to believe on that one. to overseas suppliers operating with absolutely no quality assurance whatsoever. If you are choosing to use BPC-157, you have to understand who’s manufacturing it for you, where you are getting it from, how pure it is. Dr. Deb Muth 23:26You want to make sure that you have the certificate of analysis and that it does not contain bacterial endotoxins that can contaminate the peptide or degrade the peptide and cause other issues for you. So when you talk about peptides with patients regarding BPC-157 or if you’re listening to this and you’re already using BPC-157 or other peptides, that are quote-unquote not for human consumption, an evidence-based response acknowledges both the appeal and the limitations. And you want to talk about the animal data that’s definitely showing some progress and some potential, but we don’t know what we don’t know in humans. If people are willing to take that risk, that is up to them to do that. But using BPC right now is experimental and people need to be aware of that. Are there evidence-based alternatives for patients with tendon or ligament injuries? Dr. Deb Muth 24:26And there are. There’s PRP, which has been studied in multiple randomized controlled trials. for conditions like lateral epicondylitis, tennis elbow, Achilles issues, patellar issues, knee issues. However, I want to caution you on this too. So the study that was done by Cox and colleagues in muscles, ligaments, and tendons in the Journal of 2014 showed modest benefits in pain and function compared to controls. And though the effects vary by injury type, PRP preparations can be helpful. You have to understand that a lot of times when people are doing PRP injections in their office, they are not doing it exactly the same way it was done in the study. And not to mention, if you’re using your own PRP to heal a ligament or a tendon or help your arthritis and you’re 60 or 70 years old, That is not good quality protein rich plasma. It is old protein rich plasma. And you’re not going to see necessarily the same benefits that you would see if you were using placental tissue or umbilical tissue. Dr. Deb Muth 25:33You also want to address the nutritional deficiencies or support that’s needed for connective tissue healing. And these are collagen peptides dosed at 15 grams a day. And this has been shown in a study by Shaw and colleagues in the American Journal of Clinical Nutrition in 2017 to augment collagen synthesis when combined with intermittent loading. Vitamin C is also an essential cofactor for collagen production and stabilization of collagen structure at a dose of around 500 to 1000 milligrams a day to support this process. You also need to have good adequate intake of copper and zinc. These are cofactors in collagen. Silica is also important. This comes from horsetail extract. This provides additional support as well. So more importantly, I think remembering that rehabilitation matters as well. Doing these protocols without doing some rehab is not going to get you where you want to go. Dr. Deb Muth 26:33There’s a research study by Alfredson and others for Achilles tendinopathy using the control lengthening of muscle tendon units under load to promote tendon remodeling and healing. These protocols have solid evidence and cost nothing beyond professional guidance from a physical therapist. They are important for patients seeking cutting edge regenerative approaches. Stem cell therapies, growth factors, concentrates derived from patients’ own tissues like PRP. These have a lot of good endogenous materials and they have good safety profiles. BPC-157 represents the perfect example of how promising Preclinical science gets marketed far beyond the evidence and it may eventually prove to be valuable. I think it will. But right now that determination does require some human studies and hopefully with the administration that we have right now and Bobby Kennedy, we will actually start to see some of that occur. Now the next peptide I want to talk about is TB4, thymus and beta-4. Dr. Deb Muth 27:36This is a wound healing peptide. It is a 43 amino acid peptide that’s naturally present in virtually all human cells except red blood cells. It’s actually one of the most abundant peptides in the human body, particularly concentrated in blood platelets, wound fluid, and many tissues. It’s naturally ubiquity makes it mechanistically interesting. The body wouldn’t produce it in such abundance if it didn’t serve a function. So the primary role of TB4 involves building G-actin. It’s a form of monomeric actin. And it’s structural protein that forms the microfilaments within the cells, providing cellular structure and enabling cell movement. TB4 prevents from F-actin filaments. I’m not going to talk too much about this. It’s really critical for wound healing as cells need to migrate into the injury sites. Dr. Deb Muth 28:37so the cell shape changes and the cellular response to the injury. So think of this as though you tore your meniscus and the body created all this TB4 to come to that injury to try to heal that site. That’s exactly what the TB4 is doing inside the body when there’s an injury. It’s been shown in research to help produce new blood vessel formation, promote endothelial cells, It helps modulate inflammatory cytokines, potentially reducing TNF-alpha, IL-1, and possibly protecting in programmed cell death, which we call apoptosis. And some studies suggest that it is cardioprotective in its effects in animal models of myocardial infarction, so heart attack, and neuroprotective in other models for brain injury. Now, these remain to be preliminary, but they are being seen. So the regulatory status on TB4 can create some confusion. Dr. Deb Muth 29:40The natural TB4 molecule itself is not FDA approved as a drug. However, TB4 based drug candidates called RGN259, formerly TB4, has been in the development by regen tree for corneal injuries of the dry eye disease. And as of recent updates, this drug is completed phase three trials for its neurotrophic keratopathy, severe corneal condition. But the FDA approval is still pending. So that means that the most advanced TB4-based pharmaceuticals hasn’t yet crossed the finish line for approval. The commercial peptide market further muddies the picture with TB500, which is often described as the synthetic fragment of TB4. However, this extract’s relationship between TB500 and TB4 varies depending on the source. Dr. Deb Muth 30:41So some claim that TB500 is identical to TB4, but positions 1 through 4 suggest it’s a different fragment. and the quality control across suppliers is not existent. So this confusion is part of why recommending TB500 becomes problematic for practitioners and patients, often because they aren’t certain what molecule they’re actually getting. The evidence base for TB4 in humans is limited, primarily to eye research, and the studies from Sohn’s and colleagues published in journals like Vitamins and Hormones in 2016 have examined topical TB4 for corneal injuries and neurotrophic keratopathy, dry eye, and other surface diseases. Now, these studies showed some promise in promoting this, and there is, however, a topical application to the cornea that is vastly different from a systemic injection. So for systemic use in wound healing, musculoskeletal issues, Dr. Deb Muth 31:42cardiac protection, neuroprotection, human clinical trials. There is scarce to non-existent evidence in humans. Most of the evidence remains in animal models or cell culture studies. And a review by Flip and colleagues in the Journal of Investigational Dermatology in 2006 detailed TB4’s effects on the matrix remodeling during wound repair in animal models, showing effects on collagen disposition, granulation, tissue reformation, and wound contraction. Another review by Ho and colleagues in expert opinion on biological therapy in 2007 discussed TB4’s potential in tissue regeneration and regenerative medicine, but noted the field remained largely blank. preclinical. So this is really important again to understand that there is just not enough human data. So there is a concern with cell division and migration. This theoretically exists Dr. Deb Muth 32:45for the potential effects on cancer cells, which would also rely on migration and division and other intended consequences of disrupting normal cellular architecture. These aren’t proven risks, but they are unexplored questions that we need to be aware of when we’re using peptides. This can cause cancerous tissue to grow. Very similar to what we talked about with BPC-157. These are also sold as research chemicals. There is no FDA oversight. So purity, potency, contaminations all still exist for these peptides. Now from an integrative perspective, the natural presence of TB4 in wound fluid and its biological roles in healing are legitimate science. in presence does not equal therapeutic utility. The body tightly regulates where and when and how much TB4 is present through natural production and bypassing that regulation with external dosing may or may not cause us to have beneficial or introduce risk. Dr. Deb Muth 33:49So we need to know that this is experimental use. Those people who are seeking wound healing and tissue repair the evidence-based approach of the body’s own capacity to heal is huge definitely want to be increasing your protein intake optimizing your zinc copper vitamin c and vitamin a and then managing glucose is really important during this time as well so let’s talk about a fun topic now and that’s growth hormone secretagogues this is the anti-aging hype machine these peptides in this category are things like semoralin ipameralin cjc 1220 1295 and others and among the most aggressively marketed in anti-aging and longevity medicine they all share a common goal stimulating the pituitary gland to release more growth hormone and the appeal is understandable. GH levels decline with age, and this decline is associated with increased fat mass, decreased lean muscle, reduced bone density, and other aspects of aging. Dr. Deb Muth 34:55The other times we’ll see growth hormone levels decline significantly is with chronic illness, and the logic is to restore youthful GH levels and youthful physiology. Now, semirelin from an FDA approved diagnostic to compound anti-aging product. Semirelin is a 29 amino acid peptide representing the first 29 amino acids of the full 44 amino acid human growth releasing hormone, GHRH. We talked about this on another episode of the podcast. And you can go back and listen to that one a little bit if you want. This fragment contains the complete biological activity of the full GHRH molecule and it binds to GHRH receptors in the anterior pituitary and stimulates growth releasing peptides, growth hormone releasing peptides. Semirelin was previously FDA approved as diagnostic testing of growth hormone secretion, essentially, to determine if the pituitary could still respond to GHRH stimulation in patients being evaluated for growth hormone deficiency. Dr. Deb Muth 36:06However, the manufacturer was discontinued and there was no longer an FDA approved semirelin product on the market in the United States. What exists now is semirelin available from compounding pharmacies used off label for anti-aging, body composition, and general growth hormone optimization purposes. This represents a significant gray area. Again, compounding medications serve a very important role, but they need to meet certain recommendations and regulations, as we’ve talked about in the past. You want to make sure that your compounding pharmacy that you’re obtaining semirelin from is qualified to do that, that they are doing best practices, and that you’re getting a good product. The theoretical advantage to semirelin over direct growth hormone administration is that it preserves more of the physiological growth hormone secretion patterns. Natural GH is released in pulses, primarily during sleep, not as a continuous elevation. Dr. Deb Muth 37:07So semirelin stimulates the pulses rather than providing a constant super physiological growth hormone level. And that pulsatile pattern is thought to reduce some of the side effects and metabolic concerns that we have with continuous growth hormone exposure. However, the evidence supporting semirelin for anti-aging and body composition in healthy adults is minimal. Most of the data comes from studies conducted in the 1990s when the FDA approved product existed. Not that that means it’s bad. We have drugs that have been in the market for over a hundred years that are still there, that still have the research and are still being used successfully and safely today. So we don’t want to let that really make us think that this product isn’t safe. So a 2006 review from Walker in Clinical Interventions of Aging suggested that semirelin might be a better approach than direct GH for adult onset growth hormone insufficiency, but they do acknowledge that the evidence was limited. Dr. Deb Muth 38:12And although we don’t have any large scale trials that we can examine for semirelin’s efficacy, it is now commonly prescribed. And the optimal dosing for anti-aging purposes is still unknown. It is considered experimental and it does vary from person to person, but it is still unstudied. The effects on cancer risk, cardiovascular disease, metabolic dysfunction over long time periods are also still unknown. I would argue that the side effects or the risk factors of not having growth hormone are equally as bad as the unknowns that we have here. We’re not looking to try to get super physiological doses. We’re trying to restore youthful GH levels. Typically, we’re not trying to restore back to a 20-year-old. We’re trying to restore back maybe 10 years. That is a better way of doing this. And I think that’s important for people to understand. Now, ipamirelin is the ghrelin mimicker. Dr. Deb Muth 39:12Ipamirelin is a pent-up peptide, five amino acid, that acts as a growth hormone secretagogue receptor, a GHS-R agonist. It mimics the action of ghrelin, the hunger hormone, that also stimulates growth hormone release. The proposed advantage over earlier secretagogues is that ipamirelin stimulates growth hormone release without significantly affecting cortisol, prolactin, or other glucose things, which can be increased by growth hormone secretagogues. The regulatory status is clear. Ipamirelin is not FDA approved for any indication. It’s sold as a research chemical. Human evidence is thin. It’s limited to single dose studies examining how quickly it’s absorbed and metabolized with minimal data on dosing and clinical outcomes. Now there are marketing claims for ipamirelin and they are extensive. Dr. Deb Muth 40:13It increases lean muscle mass, it decreases body fat, it improves sleep quality, faster recovery from workouts, enhanced injury healing, better skin quality. The evidence supporting these claims in humans is not available we don’t have it these are claims that are made by the effects that we know from growth hormone so it’s not necessarily a bad thing we know what growth hormone does we know growth hormone does all of these things if ipamorelin is a precursor to that it will obviously help improve those things making that correlation of what growth hormone does So there are safety concerns that mirror the same as any other growth hormone elevating therapy. It can cause fluid retention, joint pain, carpal tunnel syndrome, insulin resistance, glucose intolerance, and theoretically, can it increase calcium? cancer risks? It can because IGF-1 promotes cell proliferation and can inhibit apoptosis in cancer cells. Now remember, your body makes IGF-1. Dr. Deb Muth 41:15If it’s not making enough of it, that’s a problem. If it’s making too much of it, That’s a problem. So just understand that if you are adding these things, and especially in elevated doses, you are taking a potential risk. So there is also now CJC 1295 is a modified GHRH analog of 30 amino acid peptide based on GHRH structure, but with modifications. So it includes the addition of drug affinity complex, DACC, DAC, which involves conjugation with a small albumin binding molecule, dramatically extends the peptide’s half-life from minutes to as much as potentially a week or more. And this creates sustained growth hormone elevation rather than that pulsatile release. There are actually two versions of this. There’s CJC 1295 with DAC, longer acting version, and CJC 1295 without DAC, which is essentially a shorter duration of semirelin. Dr. Deb Muth 42:19And so when we’re comparing products, it is… only the difference between long acting and short acting. The human evidence for CJC 1295 is limited to a single published phase one study by Techman and colleagues in the Journal of Clinical Nutrition and Metabolism in 2006. And the study involves 18 healthy young adults showed that CJC 1295 with DAC produced a sustained elevation of GH and IGF-1 lasting several days after the injection. That’s essentially the entire published human evidence of this peptide. There are no phase two studies examining optimal dose. So that is all considered experimental. And there is no phase three studies examining clinical efficacy. So the sustained GH levels created by CJC 1295 with DAC raises specific concerns because the natural GH secretion It goes up and down, up and down, up and down. Dr. Deb Muth 43:19And that constant elevation may have a different metabolic and cellular effect. And we just really don’t know what that’s going to be yet. So we can understand that elevated IGF-1 levels can theoretically increase cancer concerns and metabolic risks. So rather than always injecting peptides, which are very expensive… You can do other things. And there was a study by Hartman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 1992 that demonstrated the 48-hour fast increased integrated growth hormone secretion five-fold through increased GH levels. Now, the problem with this is fasting for 48 hours is a challenge. And how long is it going to increase the growth hormone secretion without causing issues? Or in general, how long is it going to go up? Dr. Deb Muth 44:19So we have to be cautious about that as well. Sleep optimization is non-negotiable. The majority of growth hormone secretion occurs during sleep, slow wave sleep, typically the first sleep cycle, and poor sleep quality or insufficient sleep typically. can dramatically affect your growth hormone levels. And then high intensity interval training, HIIT resistance training can stimulate growth hormone as well. This was seen in a study by Godfrey and colleagues in sports medicine in 2003 and was examined in exercise-induced growth hormone responses to athletes. So we definitely see these kinds of things. So let’s talk about some longevity peptides now. These expand the telomere. So there’s epitalin and epithalamin and when these are used in anti-aging they can produce some amazing results. Dr. Deb Muth 45:22So epitalin is a synthetic terapeptide, just four amino acids. It was originally synthesized as a simplified version of epithalamine. a pineal gland extract containing multiple peptides. The synthetic four amino acid version was created to isolate what researchers believed might be the active anti-aging component. The mechanism produced for epitalin centers on telomere and telomerase, Telomeres are protective caps at the end of the chromosomes consisting of repetitive DNA sequencing. And every time a cell divides, telomeres shorten slightly because DNA polymers cannot fully replicate the ends of the linear chromosomes. So this progressive shortening acts as a molecular clock. After 50 or 70 divisions, the telomeres become critically short, triggering a cellular senescence. Dr. Deb Muth 46:22This telomere shortening is one mechanism of cellular aging and telomeres in the enzyme that can rebuild telomeres by adding these caps back onto the end of the chromosome. It’s active in stem cells, germ cells, and unfortunately in about 85 to 90% of the cancer cells. In most adult somatic cells, telomerase is inactive or present at very low levels, allowing the telomeres to shorten with division. The research on epitalin suggests it might activate this telomeres act telomeres process primarily from a research group led by Vladimir in Russia. Vladimir Kavasan in Russia. He is a huge peptide researcher or was he passed away with publications dating back to the early 2000s and a study published in bio gerontology in 2000 by Kavasan Dr. Deb Muth 47:25and colleagues examined the effect of epitalin on the lifespan of fruit flies, and they treated fruit flies that showed a modest increase in mean and maximum lifespan compared to its controls by approximately 10 to 15% lifespan extension in some experimental groups. And there were other studies in 2003 that examined epitalamine in a female Swiss-derived mouse. This was done by Ann Simove and colleagues. And the researchers reported that epitalin treatment was associated with increased lifespan as well. And the most cited mechanistic work comes from cell culture studies. And that is also Cavason’s group that published this research in 2003, showing increased telomeres activity in cultured somatic cells again. More recently, between 20 and 25, the series of publications have continued to explore epithelial effects on telomere dynamics in cell cultures. Dr. Deb Muth 48:32So there is a lot of research that’s been done. The mass majority has been done on epithelin. And most of it has been done by a single research group in Russia. There is some restrictions on some of the cell culture data that we’re seeing. And it does show that epithelin sometimes can be described as a regulating hormone. Carcadian rhythm for melatonin production, which is derived by the penile extracts. And however the evidence for this affects minimally and mechanistically unclear, the pineal gland primarily functions as melatonin secretion in that light-dark cycles. So Epithalin or epitalin is not FDA approved. It is not approved for any major regulatory jurisdiction. It is sold as a research chemical only. Dr. Deb Muth 49:33So you need to follow the same safety profiles that we’ve talked about in other episodes and in today’s episodes. And when we’re talking about epithalin, and we’re excited about it being an anti-aging science, we should balance this with the honesty and the evidence of the quality of that evidence. We don’t know its safety effect. We don’t know if it’s going to increase the risk of cancer. We can’t verify that. And we need to be using it in an experimental use of unknown risks only. Of course, diet, physical activity, stress management, sleep quality, all of those things are important for us to be looking at when we’re looking at these peptides. Now, I want to get into some of the brain peptides. This is the nootrophic frontier. C-Max and C-Lank, there is Russian pharmacology that’s done. C-Max and C-Lank represent an interesting case study in how different regulatory environments and research traditions Dr. Deb Muth 50:36create challenges in evaluating this evidence. Both peptides were developed in Russia, are approved for their specific indications and have substantial Russian language and literature supporting their use. However, the FDA approval in the United States is still not there. C-Max is a seven amino acid. It’s a synthetic analog. It is a fragment, particularly ACTH 4 through 10. It’s sometimes called the melanocortin effects because it involves the melanocortin receptors of the central nervous system. CMAX was developed by the Institute of Molecular Genetics of Russia Academy of Sciences and is approved in Russia for several indications, including acute stroke, transient ischemic attacks, cognitive disorders. It has Russian approval and is based on clinical trials primarily in Russia. Dr. Deb Muth 51:39It does help to increase brain-derived neurotrophic factor, BDNF, a protein critical for neuroplasticity, the brain’s ability to form new connections and adapt to the challenges. BDNF supports neuronal survival and promotes growth of these new neurons. C-Max also influences neurotransmitter systems, particularly dopamine and serotonin, and there is some research that suggests it affects on metabolism as well, and endogenous opioid peptides that involve pain reception and mood regulation. So it has some good potentials there. There is also C-Link, which is a hepatopeptide structurally similar to Tufts’ and an immune modulatory peptide. It was also developed in Russia and was approved for anxiety disorders as a neurotropic. Its effects involve anxiolytic effects, possibly through the GABAnergic system or the GABA system of the brain, and immune modulation. Dr. Deb Muth 52:44The Russian research is examined by C-Link for anxiety disorders. and finding reductions in anxiety without sedation. There is a dependency potential or cognitive impairment does not exist like it does with benzodiazepines with C-Link. So that is really good. And they do report attention and memory improvement using C-Link. There is a study that was done in neuroscience and behavioral psychology in 2018 that examined C-Linx effects and proposed that it exerts cytoprotective effects through BDNF pathways similar to C-Max. So both of these are Russian research-based They’re not wrong or fraudulent. It’s just that they are from Russia and we all have our concerns with Russia. However, that does not necessarily mean their research doesn’t hold quality. Dr. Deb Muth 53:49Neither peptide is approved by the FDA, and so you are using this off-label. The same rules apply for all of the other peptides that we’ve talked about that are produced off label. You want to do the same things that you would do with anything else. Good protein, omegas, B vitamins, acetylcarnitine, exercise, sleep, all of that still applies when we’re using these peptides. So I want to talk briefly about clinical decision and framework when we’re looking at this. First and foremost, we always want to go to FDA-approved peptides. Secondly, we would look at international approval with peptides that are established in other countries but lack FDA approval. And then preclinical evidence only or experimental peptides. These can be used, but they are not ethically recommended in the traditional medicine world. Dr. Deb Muth 54:50 If patients use them, we need to have appropriate counseling about the evidence surrounding them, the safety, and where to find them. how to find them and how to ask for these certificates of analysis. So I think it’s really good that we were exploring all these peptides and understanding what they are. There’s a lot of controversy out there. There’s a lot of concern out there. And what we can say with confidence is that peptides are powerful biological signaling molecules. Some peptide based medications, semi-glutide, triseptide, PT 141, Lupron that are all FDA approved. can dramatically improve outcomes in patients that are obviously selected for the correct ones. There are many other peptides that we address that are integrative and longevity space in the regenerative medicine. These peptides are all experimental. That does not automatically make them wrong. Dr. Deb Muth 55:50It just means that we need to be honest about what we’re doing with them and we need to be cautious with the patients so that they can make a decision to be part of an experimental study. in looking at how to use these peptides. So peptides are tools like any other tools. They work best in the hands of skilled people, and they are applied to appropriate situations, integrating into comprehensive approaches that address root causes. The most powerful peptide administered to a patient with untreated inflammation, hormonal chaos, nutritional deficiencies, and disorders of sleep will disappoint. The simplest evidence-based interventions apply. to a patient whose foundational physiology has been optimized. And this is the art of the science of peptide, right? If done right, respecting both the power of these molecules and the complexity of human beings that we are privileged to serve can make a difference in their lives. So thank you for listening to this episode. Dr. Deb Muth 56:52I hope this was helpful. If you can know of somebody that might benefit from this, please like, share, and subscribe. It means a lot to us. And I hope you join us for our next episode of Let’s Talk Wellness Now. Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Please note that the views and information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its management, or our partners. Each affiliate, sponsor, and partner is an independent entity with its own perspectives. Today’s content is provided for informational and educational purposes only and should not be considered specific advice, whether financial, medical, or legal. While we strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique circumstances. We encourage you to consult with a qualified professional to address your individual needs. Dr. Deb Muth 57:54Your use of information from this broadcast is entirely at your own risk. By continuing to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its associates harmless from any claims or damages arising from the use of this content. We may update this disclaimer at any time and changes will take effect immediately upon posting or broadcast. Thank you for tuning in. We hope you find this episode both insightful and thought-provoking. Listener discretion is advised.The post Episode 258 – Investigational Peptides: What's Promising, What's Hype & What You Must Know first appeared on Let's Talk Wellness Now.

Biofilm is “comprised of living cells and a structure to protect them . . . that has potentially infectious material within it.” The structure creates a physical barrier between the microorganisms and their environment, providing protection from cleaning chemistries, disinfectants, antibiotics and the body's immune system. In episode 143, host Jon Wood speaks with Dr. Jon Burdach of Nanosonics. They discuss all things biofilm: what it is, how it develops and why it is so persistent. Dr. Burdach explains the difference between preventing biofilm and removing it, and he makes a compelling case for why removal is more important. He references recent studies, including those revealing that commonly used chemicals can act as fixatives and exacerbate biofilm growth. Dr. Burdach also reviews what can happen when biofilm is introduced into the body and its role in hospital-acquired infection (HAI) outbreaks over time. Lastly, the conversation turns to the particular challenge of cleaning flexible endoscope channels. Dr. Burdach introduces the cyclic-buildup biofilm (CBB) research model and shares developments in emerging lumen cleaning technologies. This episode of Process This! addresses the far-reaching implications of biofilm and what SP professionals can do to help. “If we are better armed with the right knowledge, we can do better by our patients,” said Dr. Burdach. “Processing instruments is hard . . . but the people that do it are really what makes all the difference.” ABOUT OUR GUEST Jon Burdach, PhD Vice President of Medical Affairs Nanosonics, Inc. Jon Burdach is a medical affairs executive with extensive experience in clinical research. At Nanosonics, he is responsible for developing and executing the company's medical strategy, including healthcare professional engagement, scientific communications and medical education initiatives. He also oversees clinical research and R&D activities. He has worked in medical microbiology, genetics of anti-microbial resistance, molecular biology, and medical research within infection prevention. Dr. Burdach is an international speaker, author of numerous scientific publications, and committee member for AusMedTech NSW and AAMI. He holds a PhD in Biochemistry and Molecular Genetics from the University of New South Wales. Earn CE Now

In this episode of The Poultry Nutrition Blackbelt Podcast, Dr. Sami Dridi from the University of Arkansas explains the molecular and physiological impact of beta mannan on poultry health and performance. He breaks down how beta mannan triggers inflammation, affects gut integrity, and reduces feed efficiency, and he shares research on how beta mannanase can counter these challenges. Listen now on all major platforms!"Beta mannan creates physiological, immunological, and metabolic challenges that influence overall nutrient use and bird performance."Meet the guest: Dr. Sami Dridi is a Professor at the University of Arkansas, leading the Laboratory of Avian Endocrinology and Molecular Genetics within the Center of Excellence for Poultry Science. His research explores heat stress responses, intestinal integrity, and metabolic disorders such as muscle myopathies in poultry. His recent work examines beta mannan and beta mannanase effects on performance and gut health. Listen to this Poultry Nutrition Blackbelt Podcast episode with Dr. Sami Dridi on all major platforms.Liked this one? Don't stop now — Here's what we think you'll love!What you'll learn:(00:00) Highlight(01:39) Introduction(03:45) Beta mannan effects(05:19) Gut integrity impact(06:57) Enzyme function(07:46) Performance results(10:50) Future applications(13:07) Closing thoughtsThe Poultry Nutrition Blackbelt Podcast is trusted and supported by innovative companies like: BASF* Kemin* Fortiva- Anitox- Poultry Science Association- DietForge

Send us a textDr. Casey Perley, Ph.D. is Executive Director of the Army Applications Laboratory ( https://aal.mil/ ) where she leads the mission to reshape how the U.S. Army works with industry to provide the best tech in the world to the best Army in the world. Her vision is for AAL to work from problem inception to sustainment hand in glove with stakeholders across the Army and the Department of War to accelerate and assess the Army's ability to ingest innovation.Dr. Perley previously served most recently as the deputy director of AAL and before that as the first director of Insights and Analysis, where their scientists and entrepreneurs collaborate to bring the best companies and technologies into solving Army problems. Prior to AAL, Dr. Perley was a postdoctoral fellow at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), where she managed research projects across a range of topics and stakeholders. She designed DNA vaccines and worked in the lab with bio threats including Ebola. Dr. Perley holds a Ph.D. in Molecular Genetics and Microbiology from Duke University and a BS in Molecular Biophysics and Biochemistry from Yale.Dr. Perley's is also an accomplished harpist, and her orchestral harp work can be heard on more than 120 recordings, one of which was nominated for two Grammy awards.#CaseyPerley #ArmyApplicationsLaboratory #USArmyTransformationAndTrainingCommand #ArmyFuturesCommand #UnitedStatesArmyTrainingAndDoctrineCommand #DepartmentOfTheArmy #AutonomousBridgingKit #CasualtyCareTraining #QuantumHardening #ModularElectromagneticWarfarePayload #BroadAgencyAnnouncement #DisruptiveApplications #USAMRIID #USArmyMedicalResearchInstituteOfInfectiousDiseases #Hanta #Ebola #Tuberculosis #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcastSupport the show

Send us a textDr. Christie M. Ballantyne, MD is a Cardiologist and is one of the nation's foremost experts on lipids, atherosclerosis and heart disease prevention. He holds many leadership positions at Baylor College of Medicine ( https://www.bcm.edu/people-search/christie-ballantyne-17846 ), including director of the Center for Cardiometabolic Disease Prevention, co-director of the Lipid Metabolism and Atherosclerosis Clinic, and chief of the Section of Cardiology. With over 1000 publications in the area of atherosclerosis, lipids, and inflammation, Dr. Ballantyne's research on heart disease prevention has led him to become an established investigator for the American Heart Association and the recipient of continuous funding from the National Institutes of Health with a core focus on in basic research of leukocyte–endothelial interactions, translational research in biomarkers, and clinical trials.Dr. Ballantyne's many accomplishments have included being elected as Fellow of the American Association for the Advancement of Science, the American Society of Clinical Investigation, and the Association of American Physicians. In 2012, he received the American College of Cardiology Distinguished Scientist Award (Basic Domain). In 2014 and 2015, Thomson Reuters recognized Dr. Ballantyne as one of “The World's Most Influential Scientific Minds.” Clarivate Analytics, Web of Science, named Dr. Ballantyne as a “Highly Cited Researcher” 2017-2022 in the top 1% of researchers most cited. In 2019, Dr. Ballantyne was awarded the Baylor College of Medicine Michael E. DeBakey, M.D., Excellence in Research Award. His research in biomarkers has led to the FDA approval of 2 biomarkers for cardiovascular risk prediction, and he has played a prominent role in the development and FDA approval of new therapies for treatment of lipids.Dr. Ballantyne also serves on the Editorial Board for Circulation and the Journal of the American College of Cardiology. He received his MD from Baylor College of Medicine with internal medicine residency at The University of Texas Southwestern Medical School and cardiology fellowship at Baylor College of Medicine and an AHA fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor.Dr. Alexander Tal, MD is an accomplished and recently retired board-certified Endocrinologist ( https://www.doximity.com/pub/alexander-tal-md ) with extensive training from institutions like Baylor College of Medicine, East Tennessee State University/Quillen College of Medicine, Mount Sinai Hospital Medical Center of Chicago and Tel Aviv University Sackler, where he specialized in Diabetes, Metabolism, and Geriatric Medicine, and held Fellow status with the American Association of Clinical Endocrinology, treating various hormonal conditions.Important Episode Link - Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial - https://www.merck.com/news/mercks-enlicitide-decanoate-an-investigational-oral-pcsk9-inhibitor-significantly-reduced-ldl-c-in-phase-3-coralreef-lipids-trial/#ChristieBallantyne #Cardiologist #Lipids #Atherosclerosis #HeartDiseasePrevention #BaylorCollegeOfMedicine #CardiometabolicDisease #LipidMetabolism #Cardiology #AlexanderTal #Endocrinologist #Diabetes #Metabolism #GeriatricMedicine #Merck #Enlicitide #OralPCSK9Inhibitor #Statins #Ezetimibe #Hypercholesterolemia #apoB #Lpa #Lipoproteins #Healthspan #Longevity #Aging #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcastSupport the show

Guest: Dr. Hans Clevers is a Professor of Molecular Genetics and Distinguished Group Leader at the University of Utrecht. In this episode, he discusses snake gut and lung organoids, transitioning from academia to industry, and the challenges and complexities of creating a cell therapy. (44:26) Featured Products and Resources: Registration and abstracts are open for the ISSCR 2026 annual meeting. Receive an offer to try IntestiCult in your lab. The Stem Cell Science Round Up Computers Made From Human Brain Cells – Researchers have shown that structured neuronal firing sequences appear in spontaneous activity of human and murine brain organoids. (2:37) Organoids Replicate Vascular Pathology – Scientists have developed a blood vessel organoid model from Hutchinson-Gilford progeria syndrome-mutant hESCs. (12:01) Effects of Spaceflight on Stem Cells – Analyses of nine astronauts before, during, and after three short-duration International Space Station missions shows space-associated stem cell hallmarks of aging and resilience. (21:14) The Role of Lysosomes in HSC Aging – Reversing lysosomal dysfunction restores youthful state in aged hematopoietic stem cells. (33:25) Photo Reference: Courtesy of Hans Clevers Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

In this episode, host Daniella dos Santos is joined by Rachel Malkani, Marie Erwood, and David Singleton from IVC Evidensia's Research Team to discuss the vital role of research in shaping modern veterinary practice.The conversation explores how evidence-based strategies are transforming clinical standards and advancing animal welfare. The team shares their focus for the year on responsible parasiticide usage, a crucial area for both animal health and environmental sustainability.They also introduce the Care Frameworks—a practical tool designed to turn research findings into actionable insights for clinicians. By bridging science with practice, these frameworks aim to strengthen collaboration with pet owners and ultimately improve the standard of care for animals everywhere.Our Guests: Rachel Malkani Rachel is IVC Evidensia's Group Clinical Research Lead. She leads on the annual research strategy, research support, and research training, and is also involved with the care frameworks and other evidence-based requests. Marie Erwood  Marie a data scientist who started her career working in academic research for human health. She uses data to help measure the impact of research at IVC Evidensia and collaborate on internal and external research projects. David Singleton Davis is Group Director of Research at IVC Evidensia. He is a veterinary surgeon with a master's degree and a PhD in epidemiology and health informatics from the University of Liverpool. Collectively, he has first or co-authored over 40 publications.  Our Host: Daniella dos Santos BSc BVetMed FRCVS  Daniella graduated from the Royal Veterinary College in 2012 having previously obtained a degree in Molecular Genetics from Kings College. She has since worked in first opinion, small animal and exotic pet practices across the Southeast. In 2019, she became the youngest-ever President of the British Veterinary Association, leading the profession through the height of the pandemic. During her time as President, she was instrumental in the association's Diversity and Inclusion work, as well as the development and launch of the Good Workplaces Policy. Daniella was the recipient on the RCVS Inspiration Award 2021 for her leadership and became an RCVS Fellow in 2021 for Meritorious Contributions to the Profession. She is a trustee of the animal welfare charity SPANA and the PetPlan Charitable Trust. Powered by IVC EvidensiaAt IVC Evidensia we're building the world's best veterinary group, with a single purpose; healthy animals and happy owners.Visit ivcevidensia.co.uk to find out more, or follow us on social media.Please note that the views expressed by hosts and guests in this podcast do not necessarily reflect those of IVC Evidensia.LinksFor IVC Evidensia colleagues visit the Research Hub on the IntranetTo contact the research team email: research@ivcevidensia.com 

We are discussing perspective changes in neurology genetics with the crossover of the APOE gene in neuro and cardio as well as telehealth for neurology predictive testing. Segment 1: Is it time for a paradigm shift? Inclusion of APOE  on genetic dyslipidemia panels.   Emily Brown is a certified genetic counselor at the Center for Inherited Heart Disease at Johns Hopkins Hospital. She graduated from the University of Maryland Genetic Counseling Program in 2014 and has practiced in cardiology for the past 10 years. Her main areas of interest include dyslipidemias, and she is a member of the National Lipid Association.   Hannah Ison is a cardiovascular genetic counselor at the Stanford Center for Inherited Cardiovascular Disease. She received her Master's in Medical and Molecular Genetics from Indiana University in 2018, and returned home to California to begin her career. Her primary clinical interest includes working with patients who have inherited lipid conditions in both the adult and pediatric setting. A large part of her role has been focused on developing a Pediatric Lipid Clinic at the Stanford Children's Hospital, allowing her to care for patients across the generations. Hannah was the co-chair of the Dyslipidemia Working Group through the cardiovascular SIG from 2020-2024 where she worked with members to develop dyslipidemia resources. In addition to her work in the lipid space, she also provides inpatient and outpatient genetic counseling to patients with isolated congenital heart disease, and enjoys participating in various research opportunities.    In this segment we discuss: - APOE's relevance in both Alzheimer's and cardiovascular disease - Counseling strategies for APOE alleles (ε2, ε3, and ε4), including penetrance, lifestyle modification, and exploration of risk for conditions and symptoms external to Alzheimer's - Case studies highlighting APOE's diagnostic, variant, and treatment insights - The need for standardization, education, and reframing of APOE testing in practice Segment 2: Patient-reported outcomes for remote and in-person visits for genetic counseling in adult neurology.   Rachel A. Paul, MS, CGC and Laynie Dratch, ScM, CGC are board-certified genetic counselors who specialize in adult neurogenetics and work with the Penn Neurogenetics Therapy Center team in Philadelphia, PA (https://www.linkedin.com/company/penn-neurogenetics-therapy-center).   Rachel provides clinical and research genetic counseling services for the Division of Movement Disorders at the University of Pennsylvania. Her research interests include genetic screening for clinical trials access, remote/telemedicine genetic services, and motivations/barriers for genetics utilization. She graduated cum laude from Temple University in Philadelphia, previously worked as a genetic counseling assistant (GCA) for the Penn neurogenetics program, and completed her training with the Arcadia University (now University of Pennsylvania) Genetic Counseling Program.   Laynie's clinical focus includes frontotemporal degeneration (FTD) spectrum disorders, amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions. Her research interests include the lived experiences of at-risk individuals, predictive genetic testing considerations, and genetic counseling access and service delivery. She graduated summa cum laude from Colgate University with a BA in neuroscience and a minor in psychology, and completed her genetic counseling masters training at the Johns Hopkins University and the National Institutes of Health.   In this segment we discuss: - How COVID-19 pushed neurogenetics counseling from in-person to telehealth. - Why patient satisfaction stayed high across both formats, with video outperforming phone. - What drives visit preferences—travel, tech comfort, privacy, and clinical needs. - Future research to refine protocols, improve access, and explore broader applications.   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.    DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Stephanie Schofield.

Michael Lynch, Ph.D., Director of the Center for Mechanisms of Evolution at Arizona State University and Vaughn Cooper, Ph.D., professor of Microbiology and Molecular Genetics at the University of Pittsburgh, School of Medicine, examine the origins and trajectory of early microbial life (EML) and discuss the collaborative report between the American Academy of Microbiology and the Gordon and Betty Moore Foundation, which explores the journey of life on Earth, from non-living chemical compounds to early unicellular life, to the vast diversity of organisms we see today. This episode is brought to you by the American Academy of Microbiology, a think tank at American Society for Microbiology and the Gordon and Betty Moore Foundation, which has been dedicated to advancing scientific discovery for the past 25 years. Links for This Episode: Project Report Early Microbial Life: Our Past, Present and Future. Article: The Great Oxidation Event: How Cyanobacteria Changed Life. MTM Podcast: From Hydrothermal Vents to Cold Seeps: How Bacteria Sustain Ocean Life With Nicole Dubilier. Take the MTM listener survey! 

In this episode, Dr. Gil Blander welcomes Dr. Haim Cohen to Longevity by Design to explore his revolutionary approach to understanding aging. Haim's team analyzed acetylation sites across 107 mammalian species, creating its most extensive comparative study. This computational approach revealed specific post-translational modifications that evolved exclusively in long-lived animals.The research identifies critical pathways where evolution engineered longevity solutions. These acetylation changes affect DNA repair, cell cycle regulation, and mitochondrial function. Unlike traditional aging research focusing on single pathways like mTOR or caloric restriction, Haim's unbiased screening simultaneously reveals multiple longevity targets. Evolution provided a natural laboratory for testing anti-aging modifications over millions of years.The findings offer exciting therapeutic possibilities for human longevity. Haim's team is now creating transgenic mice to test whether mimicking these evolutionary changes can extend lifespan in the lab. This research suggests humans could potentially "accelerate evolution" by implementing modifications that nature has already proven effective in whales, elephants, and other long-lived species. Guest-at-a-Glance

In this episode, we talk to two genetic counselors about their recent publications in a special edition of the Journal of Genetic Counseling focused on research methods in genetic counseling. First, Benjamin Helm delves into statistical approaches and discusses how transparency and honesty in research can lead to more meaningful scientific contributions. Then Kennedy Borle explores the challenges and benefits of integrating qualitative and quantitative approaches in genetic counseling research.   Segment 1: “Research methods in genetic counseling: Statistical approaches and resources”   Benjamin M. Helm, PhD, MS, CGC, is an Associate Professor of Clinical Medical & Molecular Genetics at Indiana University with specific interests in cardiovascular genetics, epidemiology, and public health genomics. He works within the Cardiovascular Genetics program at IU School of Medicine/Indiana University Health. His clinical and academic interests include genetic arrhythmias, congenital heart disease, familial hypercholesterolemia and lipoprotein (a), polygenic score methods, and assessment of population screening for genetic cardiovascular disorders. Additional work extends into public health, improving investigation of genetic risk factors for sudden death in infants and children and birth defect surveillance in Indiana.   In this segment we discuss: Importance of systematic bias and robust study design Understanding parametric research: assumptions, sample size, and data behavior Common misconceptions, such as the over-reliance on p-values for legitimacy and the pitfalls of p-hacking Encouragement for genetic counselors to engage with statistical research   Segment 2: “Using mixed methods for genetic counseling research”   Kennedy Borle is a board-certified genetic counsellor and PhD Candidate in Interdisciplinary Studies at the University of British Columbia. Her research is focused on understanding unmet need for clinical genetic services to improve equitable access to care. Kennedy is also passionate about promoting high quality and justice oriented genetic counselling research practices.   In this segment we discuss: The complexities and advantages of using mixed methods in genetic counseling Challenges of integrating qualitative and quantitative data The importance of rigorous planning and study design How collaboration can enhance research outcomes   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.  Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.  DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Stephanie Schofield.

Dr. Clara Peek, assistant professor of Biochemistry and Molecular Genetics and Medicine in the Division of Endocrinology, is here to walk us through a new Northwestern Medicine study she led that was published in Science Advances, suggesting that circadian rhythms play a role in how quickly damaged muscles heal.

The Smart 7 is an award winning daily podcast, in association with METRO that gives you everything you need to know in 7 minutes, at 7am, 7 days a week...With over 18 million downloads and consistently charting, including as No. 1 News Podcast on Spotify, we're a trusted source for people every day and the Sunday 7 won a Gold Award as “Best Conversation Starter” in the International Signal Podcast Awards If you're enjoying it, please follow, share, or even post a review, it all helps...Today's episode includes the following guests:GuestsMartin Kulldorf - Professor of Medicine and member of ACIP Kim Schrier - Democratic Congresswoman, WAProfessor Elizabeth Whittaker - Paediatric Expert in Infectious Diseases Will Guyatt - The Smart 7's Tech Guru Doctor Helen O'Neill - Associate Professor of Molecular Genetics at University College LondonProfessor Rameen Shakur - Professor of Genomics at the University of Brighton William O'Mullaine Associate Director for Data Production at the Vera C Rubin Observatory, Chile Elon Musk - Founder and CEO of NeuralinkPaolo Ardoino - CEO of Tether T - a car thief interviewed by Channel 4's DispatchesIan Thwaites - Police Constable from the Port of Dover Police Anthony Alexander - Peace Park Foundations Programme Manager Contact us over @TheSmart7pod or visit www.thesmart7.com or find out more at www.metro.co.uk Presented by Ciara Revins, written by Liam Thompson, researched by Lucie Lewis and produced by Daft Doris. Hosted on Acast. See acast.com/privacy for more information.

Dr. Shannon Manning is a Michigan State University (MSU) Foundation Associate Professor in the Department of Microbiology and Molecular Genetics. The goal of Shannon's research is to understand how pathogens (bacteria or viruses) cause disease in people. How likely a person is to get sick may be due to the different types of pathogens they are exposed to, but also genetic variation within a specific type of pathogen. Not every bacteria of a particular species is exactly identical, and some are more effective at attaching to targets and infecting hosts. When she's not working in the lab, Shannon loves spending time with her family. On the weekends, Shannon can often be found at soccer games, swim meets, and other activities cheering on her four kids. Gardening is also one of her favorite hobbies, and she has been cultivating a wonderful assortment of flowers. She earned her B.S. in biology from the University of Michigan, her M.P.H. in Hospital and Molecular Epidemiology, and her Ph.D. in Molecular Epidemiology from the University of Michigan. Afterwards, Shannon was awarded an Emerging Infectious Disease Postdoctoral Fellowship from the Center for Disease Control and Prevention. Shannon is with us today to tell us all about her journey through life and science.

Please join my mailing list here

In this episode we are exploring two publications related to cancer care. In our first segment we talk to 2 authors about their research on genetic counselors and identification of patients for high-risk pancreatic cancer screening. In our second segment, Khalida interviews a genetic counselor about their study to evaluate surgical patient perspectives of genetic testing provided by a non-genetics professional.  Segment 1: “Practices and perspectives of genetic counselors about high-risk pancreatic cancer screening: A cross-sectional survey study” Amy Wiegand is a board-certified genetic counselor who specializes in cancer genetics. She graduated with her Master's in Genetic Counseling in 2017 from from the Icahn School of Medicine at Mount Sinai and has worked as a cancer genetic counselor at the Smilow Cancer Genetics and Prevention Program at Yale-New Haven Health since 2017 where she has seen over 2500 patients for a variety of hereditary cancer indications. Her research interests include hereditary pancreatic cancer and alternative delivery care models for genetic testing. Aparna is a senior genetic counseling assistant (GCA) at Smilow Cancer Genetics and Prevention Program at Yale New Haven Health where she has worked since 2019, and she has over 6 years of experience as a GCA. She holds a Master's degree in Biomedical Genetics and a Bachelor's degree in Biotechnology. She also has a varied background in administration, finance and customer service. She is a high-performing individual and was recently recognized by her colleagues as ‘Employee of the Quarter' and honored by the organization as ‘Smilow Star' for consistently going above and beyond for the patients and the co-workers and for exemplifying the health system's values. She contributes to the program in a variety of other ways outside of her role and works collaboratively with the team to create a patient centered environment. She has a strong interest in Cancer Genetics and is passionate about research. She is currently working on another research project, the abstract of which was selected for presentation in a Poster Session at 2025 ASCO (American Society of Clinical Oncology) annual meeting. She enjoys being part of a collaborative and dynamic team at Smilow Cancer Genetics and Prevention program and is excited about the upcoming research initiatives in the program. In this segment we discuss: - The significance of pancreatic cancer surveillance for high-risk individuals and why early detection plays a critical role in improving outcomes. - How genetic counselors are uniquely positioned to identify and refer individuals at high risk for pancreatic cancer, emphasizing their role in screening efforts. - An overview of the 2019 CAPS (Cancer of the Pancreas Screening) consensus guidelines and how they are applied to identify high-risk individuals for surveillance - The finding that nearly 70% of genetic counselors accurately identified individuals eligible for screening and discussed the factors that may have contributed to this high rate. - The association between provider comfort level and accuracy in identifying high-risk individuals, and discussed strategies to improve provider confidence and access to screening programs.   Segment 2: “Patient experiences of cancer genetic testing by non-genetics providers in the surgical setting” Katie Fiallos is a board-certified genetic counselor who earned her Master of Science in Genetic Counseling from the Johns Hopkins University/National Human Genome Research Institute Genetic Counseling Training program in 2017 and worked for seven years as a cancer genetic counselor at Johns Hopkins. She joined the Department of Medical and Molecular Genetics at Indiana University in August 2024. She is fluent in Spanish and provides genetic counseling in English and Spanish to participants with Parkinson's disease enrolled in the PD GENEration study. She has authored several academic papers related to genetic counseling, and her current research interests include provision of genetic counseling to Latine individuals, alternate service delivery models, and patient experiences with genetic testing and their informational desires. She lives in Michigan with her family and enjoys staying active, particularly practicing aerial silks. The research for the paper we're discussing was done while she was at Johns Hopkins and was funded by the Jennifer L. Brager Memorial Research award through the Johns Hopkins Kimmel Cancer Center.   In this segment we discuss: - Why hereditary cancer genetic testing is becoming increasingly important for patients with breast cancer, especially in relation to surgical decision-making. - The findings that patients preferred genetic testing at an existing appointment shortly after diagnosis, and explored how this timing affects their overall experience. - How many patients had already considered or wanted genetic testing before it was offered, shedding light on patient awareness and readiness. - Why patients were primarily motivated by concern for relatives and a desire for complete information, rather than surgical decision-making. - Gaps in patient-provider communication identified in the study and suggested ways for providers to address these issues in clinical practice.   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.  DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Sydney Arlen.

In a major scientific breakthrough, researchers from 29 institutions across North America—led by the Allen Institute—have developed over 1,000 new genetic tools called enhancer AAV vectors to precisely target specific brain cells. Guest: Dr. Bosiljka Tasic - Director of Molecular Genetics at the Allen Institute for Brain Science Learn more about your ad choices. Visit megaphone.fm/adchoices

Johnjoe McFadden is Professor of Molecular Genetics at the University of Surrey, United Kingdom. He obtained his BSc in Biochemistry at the University of London, and his PhD at Imperial College London. He is an accomplished scientist and author. He has written several books, including "Quantum Evolution: Life in the Multiverse" (2000), "Life on the Edge: The Coming of Age of Quantum Biology" (2014), and his latest book "Life Is Simple: How Occam's Razor Set Science Free and Shapes the Universe" (2021). His research interests include systems biology, mycobacterial genetics, pathogenicity of tuberculosis, neisserial genetics, pathogenicity of meningococcal meningitis. However, along with Prof Jim Al-Khalili, he has become best-known for his contributions to the field of Quantum Biology. Prof McFadden also endorses a theory of consciousness wherein consciousness is an electromagnetic information field (known as CEMI Field Theory).Lecture Title: "Life Is Simple: Science is Occam's Razor" TIMESTAMPS:(0:00) - Introduction (1:03) - William of Ockham(4:43) - Medieval Scientific Theology(9:32) - Universals(13:05) - Teleology(19:45) - Science vs Religion(24:06) - Occam's Razor in Science(37:01) - Simple Laws & Technology (41:25) - Symmetry & Simplicity(43:32) - How Does Occam's Razor Work?(47:55) - What is Science?(51:21) - Occam's Razor in daily life ("The Pocket Razor")(53:39) - Conclusion EPISODE LINKS:- Johnjoe's Podcast: https://www.youtube.com/watch?v=0kldDplYKac- Johnjoe's Website: https://johnjoemcfadden.co.uk- Johnjoe's Publications: https://tinyurl.com/2s48mdnd- Johnjoe's Books: https://tinyurl.com/49kp3snfCONNECT:- Website: https://tevinnaidu.com - Podcast: https://creators.spotify.com/pod/show/mindbodysolution- YouTube: https://youtube.com/mindbodysolution- Twitter: https://twitter.com/drtevinnaidu- Facebook: https://www.facebook.com/drtevinnaidu - Instagram: https://www.instagram.com/drtevinnaidu- LinkedIn: https://www.linkedin.com/in/drtevinnaidu=============================Disclaimer: The information provided on this channel is for educational purposes only. The content is shared in the spirit of open discourse and does not constitute, nor does it substitute, professional or medical advice. We do not accept any liability for any loss or damage incurred from you acting or not acting as a result of listening/watching any of our contents. You acknowledge that you use the information provided at your own risk. Listeners/viewers are advised to conduct their own research and consult with their own experts in the respective fields.

How do the arts help us find purpose and meaning? What role do stories play in helping us preserve memories, connect us to each other, and answer life's big questions?MAX RICHTER(Award-winning Composer & Pianist · His album Sleep is the most streamed classical album of all time) reflects on the importance of creativity and how literature, music, and visual art offer windows into other people's perceptions and experiences, fostering understanding and connection.ETGAR KERET (Cannes Film Festival Award-winning Director · Author of Fly Already · Suddenly a Knock on the Door · The Seven Good Years) shares insights from his upbringing and how his mother's storytelling shaped his perception of creativity and authenticity.ANTHONY JOSEPH (T.S. Eliot Prize-winning Poet, Novelist & Singer-songwriter · Author of Sonnets for Albert) discusses the fragmented documentation of Caribbean life and how his poetry attempts to piece together these fragments.CLAUDIA FORESTIERI (Emmy Award-winning Writer · Creator of HBOMax's Gordita Chronicles) talks about the crucial role of immigrants in building and revitalizing America, portraying them as "Born Again Americans."BRIGITTE MUNOZ-LIEBOWITZ (Showrunner Gordita Chronicles · One Day at a Time) highlights the inevitability of adversity in life and its role in fostering growth. She underscores the importance of a positive outlook in overcoming the challenges of immigration.JOHNJOE McFADDEN (Author of Life is Simple: How Occam's Razor Set Science Free and Shapes the Universe · Professor of Molecular Genetics at University of Surrey) explores the communicative power of art, detailing how complex ideas and feelings can be conveyed holistically.SHEHAN KARUNATILAKA (Booker Prize-winning Author of The Seven Moons of Maali Almeida) discusses his choice of writing in the second person to explore the spiritual dimension.CATHERINE CURTIN (Actress · Stranger Things · Orange Is the New Black · Homeland) reflects on creative freedom, experimental theater and her work in film and television.KATE MUETH (Founder/Artistic Director of the award-winning dance theater company The Neo-Political Cowgirls) emphasizes the importance of connecting stories to meaning and how her creative process prioritizes authenticity and personal fulfillment over industry expectations.To hear more from each guest, listen to their full interviews.Episode Websitewww.creativeprocess.info/podInstagram:@creativeprocesspodcast

How do the arts help us find purpose and meaning? What role do stories play in helping us preserve memories, connect us to each other, and answer life's big questions?MAX RICHTER(Award-winning Composer & Pianist · His album Sleep is the most streamed classical album of all time) reflects on the importance of creativity and how literature, music, and visual art offer windows into other people's perceptions and experiences, fostering understanding and connection.ETGAR KERET (Cannes Film Festival Award-winning Director · Author of Fly Already · Suddenly a Knock on the Door · The Seven Good Years) shares insights from his upbringing and how his mother's storytelling shaped his perception of creativity and authenticity.ANTHONY JOSEPH (T.S. Eliot Prize-winning Poet, Novelist & Singer-songwriter · Author of Sonnets for Albert) discusses the fragmented documentation of Caribbean life and how his poetry attempts to piece together these fragments.CLAUDIA FORESTIERI (Emmy Award-winning Writer · Creator of HBOMax's Gordita Chronicles) talks about the crucial role of immigrants in building and revitalizing America, portraying them as "Born Again Americans."BRIGITTE MUNOZ-LIEBOWITZ (Showrunner Gordita Chronicles · One Day at a Time) highlights the inevitability of adversity in life and its role in fostering growth. She underscores the importance of a positive outlook in overcoming the challenges of immigration.JOHNJOE McFADDEN (Author of Life is Simple: How Occam's Razor Set Science Free and Shapes the Universe · Professor of Molecular Genetics at University of Surrey) explores the communicative power of art, detailing how complex ideas and feelings can be conveyed holistically.SHEHAN KARUNATILAKA (Booker Prize-winning Author of The Seven Moons of Maali Almeida) discusses his choice of writing in the second person to explore the spiritual dimension.CATHERINE CURTIN (Actress · Stranger Things · Orange Is the New Black · Homeland) reflects on creative freedom, experimental theater and her work in film and television.KATE MUETH (Founder/Artistic Director of the award-winning dance theater company The Neo-Political Cowgirls) emphasizes the importance of connecting stories to meaning and how her creative process prioritizes authenticity and personal fulfillment over industry expectations.To hear more from each guest, listen to their full interviews.Episode Websitewww.creativeprocess.info/podInstagram:@creativeprocesspodcast

How do the arts help us find purpose and meaning? What role do stories play in helping us preserve memories, connect us to each other, and answer life's big questions?MAX RICHTER(Award-winning Composer & Pianist · His album Sleep is the most streamed classical album of all time) reflects on the importance of creativity and how literature, music, and visual art offer windows into other people's perceptions and experiences, fostering understanding and connection.ETGAR KERET (Cannes Film Festival Award-winning Director · Author of Fly Already · Suddenly a Knock on the Door · The Seven Good Years) shares insights from his upbringing and how his mother's storytelling shaped his perception of creativity and authenticity.ANTHONY JOSEPH (T.S. Eliot Prize-winning Poet, Novelist & Singer-songwriter · Author of Sonnets for Albert) discusses the fragmented documentation of Caribbean life and how his poetry attempts to piece together these fragments.CLAUDIA FORESTIERI (Emmy Award-winning Writer · Creator of HBOMax's Gordita Chronicles) talks about the crucial role of immigrants in building and revitalizing America, portraying them as "Born Again Americans."BRIGITTE MUNOZ-LIEBOWITZ (Showrunner Gordita Chronicles · One Day at a Time) highlights the inevitability of adversity in life and its role in fostering growth. She underscores the importance of a positive outlook in overcoming the challenges of immigration.JOHNJOE McFADDEN (Author of Life is Simple: How Occam's Razor Set Science Free and Shapes the Universe · Professor of Molecular Genetics at University of Surrey) explores the communicative power of art, detailing how complex ideas and feelings can be conveyed holistically.SHEHAN KARUNATILAKA (Booker Prize-winning Author of The Seven Moons of Maali Almeida) discusses his choice of writing in the second person to explore the spiritual dimension.CATHERINE CURTIN (Actress · Stranger Things · Orange Is the New Black · Homeland) reflects on creative freedom, experimental theater and her work in film and television.KATE MUETH (Founder/Artistic Director of the award-winning dance theater company The Neo-Political Cowgirls) emphasizes the importance of connecting stories to meaning and how her creative process prioritizes authenticity and personal fulfillment over industry expectations.To hear more from each guest, listen to their full interviews.Episode Websitewww.creativeprocess.info/podInstagram:@creativeprocesspodcast

How do the arts help us find purpose and meaning? What role do stories play in helping us preserve memories, connect us to each other, and answer life's big questions?MAX RICHTER(Award-winning Composer & Pianist · His album Sleep is the most streamed classical album of all time) reflects on the importance of creativity and how literature, music, and visual art offer windows into other people's perceptions and experiences, fostering understanding and connection.ETGAR KERET (Cannes Film Festival Award-winning Director · Author of Fly Already · Suddenly a Knock on the Door · The Seven Good Years) shares insights from his upbringing and how his mother's storytelling shaped his perception of creativity and authenticity.ANTHONY JOSEPH (T.S. Eliot Prize-winning Poet, Novelist & Singer-songwriter · Author of Sonnets for Albert) discusses the fragmented documentation of Caribbean life and how his poetry attempts to piece together these fragments.CLAUDIA FORESTIERI (Emmy Award-winning Writer · Creator of HBOMax's Gordita Chronicles) talks about the crucial role of immigrants in building and revitalizing America, portraying them as "Born Again Americans."BRIGITTE MUNOZ-LIEBOWITZ (Showrunner Gordita Chronicles · One Day at a Time) highlights the inevitability of adversity in life and its role in fostering growth. She underscores the importance of a positive outlook in overcoming the challenges of immigration.JOHNJOE McFADDEN (Author of Life is Simple: How Occam's Razor Set Science Free and Shapes the Universe · Professor of Molecular Genetics at University of Surrey) explores the communicative power of art, detailing how complex ideas and feelings can be conveyed holistically.SHEHAN KARUNATILAKA (Booker Prize-winning Author of The Seven Moons of Maali Almeida) discusses his choice of writing in the second person to explore the spiritual dimension.CATHERINE CURTIN (Actress · Stranger Things · Orange Is the New Black · Homeland) reflects on creative freedom, experimental theater and her work in film and television.KATE MUETH (Founder/Artistic Director of the award-winning dance theater company The Neo-Political Cowgirls) emphasizes the importance of connecting stories to meaning and how her creative process prioritizes authenticity and personal fulfillment over industry expectations.To hear more from each guest, listen to their full interviews.Episode Websitewww.creativeprocess.info/podInstagram:@creativeprocesspodcast

How do the arts help us find purpose and meaning? What role do stories play in helping us preserve memories, connect us to each other, and answer life's big questions?MAX RICHTER(Award-winning Composer & Pianist · His album Sleep is the most streamed classical album of all time) reflects on the importance of creativity and how literature, music, and visual art offer windows into other people's perceptions and experiences, fostering understanding and connection.ETGAR KERET (Cannes Film Festival Award-winning Director · Author of Fly Already · Suddenly a Knock on the Door · The Seven Good Years) shares insights from his upbringing and how his mother's storytelling shaped his perception of creativity and authenticity.ANTHONY JOSEPH (T.S. Eliot Prize-winning Poet, Novelist & Singer-songwriter · Author of Sonnets for Albert) discusses the fragmented documentation of Caribbean life and how his poetry attempts to piece together these fragments.CLAUDIA FORESTIERI (Emmy Award-winning Writer · Creator of HBOMax's Gordita Chronicles) talks about the crucial role of immigrants in building and revitalizing America, portraying them as "Born Again Americans."BRIGITTE MUNOZ-LIEBOWITZ (Showrunner Gordita Chronicles · One Day at a Time) highlights the inevitability of adversity in life and its role in fostering growth. She underscores the importance of a positive outlook in overcoming the challenges of immigration.JOHNJOE McFADDEN (Author of Life is Simple: How Occam's Razor Set Science Free and Shapes the Universe · Professor of Molecular Genetics at University of Surrey) explores the communicative power of art, detailing how complex ideas and feelings can be conveyed holistically.SHEHAN KARUNATILAKA (Booker Prize-winning Author of The Seven Moons of Maali Almeida) discusses his choice of writing in the second person to explore the spiritual dimension.CATHERINE CURTIN (Actress · Stranger Things · Orange Is the New Black · Homeland) reflects on creative freedom, experimental theater and her work in film and television.KATE MUETH (Founder/Artistic Director of the award-winning dance theater company The Neo-Political Cowgirls) emphasizes the importance of connecting stories to meaning and how her creative process prioritizes authenticity and personal fulfillment over industry expectations.To hear more from each guest, listen to their full interviews.Episode Websitewww.creativeprocess.info/podInstagram:@creativeprocesspodcast

How do the arts help us find purpose and meaning? What role do stories play in helping us preserve memories, connect us to each other, and answer life's big questions?MAX RICHTER(Award-winning Composer & Pianist · His album Sleep is the most streamed classical album of all time) reflects on the importance of creativity and how literature, music, and visual art offer windows into other people's perceptions and experiences, fostering understanding and connection.ETGAR KERET (Cannes Film Festival Award-winning Director · Author of Fly Already · Suddenly a Knock on the Door · The Seven Good Years) shares insights from his upbringing and how his mother's storytelling shaped his perception of creativity and authenticity.ANTHONY JOSEPH (T.S. Eliot Prize-winning Poet, Novelist & Singer-songwriter · Author of Sonnets for Albert) discusses the fragmented documentation of Caribbean life and how his poetry attempts to piece together these fragments.CLAUDIA FORESTIERI (Emmy Award-winning Writer · Creator of HBOMax's Gordita Chronicles) talks about the crucial role of immigrants in building and revitalizing America, portraying them as "Born Again Americans."BRIGITTE MUNOZ-LIEBOWITZ (Showrunner Gordita Chronicles · One Day at a Time) highlights the inevitability of adversity in life and its role in fostering growth. She underscores the importance of a positive outlook in overcoming the challenges of immigration.JOHNJOE McFADDEN (Author of Life is Simple: How Occam's Razor Set Science Free and Shapes the Universe · Professor of Molecular Genetics at University of Surrey) explores the communicative power of art, detailing how complex ideas and feelings can be conveyed holistically.SHEHAN KARUNATILAKA (Booker Prize-winning Author of The Seven Moons of Maali Almeida) discusses his choice of writing in the second person to explore the spiritual dimension.CATHERINE CURTIN (Actress · Stranger Things · Orange Is the New Black · Homeland) reflects on creative freedom, experimental theater and her work in film and television.KATE MUETH (Founder/Artistic Director of the award-winning dance theater company The Neo-Political Cowgirls) emphasizes the importance of connecting stories to meaning and how her creative process prioritizes authenticity and personal fulfillment over industry expectations.To hear more from each guest, listen to their full interviews.Episode Websitewww.creativeprocess.info/podInstagram:@creativeprocesspodcast

How do the arts help us find purpose and meaning? What role do stories play in helping us preserve memories, connect us to each other, and answer life's big questions?MAX RICHTER(Award-winning Composer & Pianist · His album Sleep is the most streamed classical album of all time) reflects on the importance of creativity and how literature, music, and visual art offer windows into other people's perceptions and experiences, fostering understanding and connection.ETGAR KERET (Cannes Film Festival Award-winning Director · Author of Fly Already · Suddenly a Knock on the Door · The Seven Good Years) shares insights from his upbringing and how his mother's storytelling shaped his perception of creativity and authenticity.ANTHONY JOSEPH (T.S. Eliot Prize-winning Poet, Novelist & Singer-songwriter · Author of Sonnets for Albert) discusses the fragmented documentation of Caribbean life and how his poetry attempts to piece together these fragments.CLAUDIA FORESTIERI (Emmy Award-winning Writer · Creator of HBOMax's Gordita Chronicles) talks about the crucial role of immigrants in building and revitalizing America, portraying them as "Born Again Americans."BRIGITTE MUNOZ-LIEBOWITZ (Showrunner Gordita Chronicles · One Day at a Time) highlights the inevitability of adversity in life and its role in fostering growth. She underscores the importance of a positive outlook in overcoming the challenges of immigration.JOHNJOE McFADDEN (Author of Life is Simple: How Occam's Razor Set Science Free and Shapes the Universe · Professor of Molecular Genetics at University of Surrey) explores the communicative power of art, detailing how complex ideas and feelings can be conveyed holistically.SHEHAN KARUNATILAKA (Booker Prize-winning Author of The Seven Moons of Maali Almeida) discusses his choice of writing in the second person to explore the spiritual dimension.CATHERINE CURTIN (Actress · Stranger Things · Orange Is the New Black · Homeland) reflects on creative freedom, experimental theater and her work in film and television.KATE MUETH (Founder/Artistic Director of the award-winning dance theater company The Neo-Political Cowgirls) emphasizes the importance of connecting stories to meaning and how her creative process prioritizes authenticity and personal fulfillment over industry expectations.To hear more from each guest, listen to their full interviews.Episode Websitewww.creativeprocess.info/podInstagram:@creativeprocesspodcast

How do the arts help us find purpose and meaning? What role do stories play in helping us preserve memories, connect us to each other, and answer life's big questions?MAX RICHTER(Award-winning Composer & Pianist · His album Sleep is the most streamed classical album of all time) reflects on the importance of creativity and how literature, music, and visual art offer windows into other people's perceptions and experiences, fostering understanding and connection.ETGAR KERET (Cannes Film Festival Award-winning Director · Author of Fly Already · Suddenly a Knock on the Door · The Seven Good Years) shares insights from his upbringing and how his mother's storytelling shaped his perception of creativity and authenticity.ANTHONY JOSEPH (T.S. Eliot Prize-winning Poet, Novelist & Singer-songwriter · Author of Sonnets for Albert) discusses the fragmented documentation of Caribbean life and how his poetry attempts to piece together these fragments.CLAUDIA FORESTIERI (Emmy Award-winning Writer · Creator of HBOMax's Gordita Chronicles) talks about the crucial role of immigrants in building and revitalizing America, portraying them as "Born Again Americans."BRIGITTE MUNOZ-LIEBOWITZ (Showrunner Gordita Chronicles · One Day at a Time) highlights the inevitability of adversity in life and its role in fostering growth. She underscores the importance of a positive outlook in overcoming the challenges of immigration.JOHNJOE McFADDEN (Author of Life is Simple: How Occam's Razor Set Science Free and Shapes the Universe · Professor of Molecular Genetics at University of Surrey) explores the communicative power of art, detailing how complex ideas and feelings can be conveyed holistically.SHEHAN KARUNATILAKA (Booker Prize-winning Author of The Seven Moons of Maali Almeida) discusses his choice of writing in the second person to explore the spiritual dimension.CATHERINE CURTIN (Actress · Stranger Things · Orange Is the New Black · Homeland) reflects on creative freedom, experimental theater and her work in film and television.KATE MUETH (Founder/Artistic Director of the award-winning dance theater company The Neo-Political Cowgirls) emphasizes the importance of connecting stories to meaning and how her creative process prioritizes authenticity and personal fulfillment over industry expectations.To hear more from each guest, listen to their full interviews.Episode Websitewww.creativeprocess.info/podInstagram:@creativeprocesspodcast

How do the arts help us find purpose and meaning? What role do stories play in helping us preserve memories, connect us to each other, and answer life's big questions?MAX RICHTER(Award-winning Composer & Pianist · His album Sleep is the most streamed classical album of all time) reflects on the importance of creativity and how literature, music, and visual art offer windows into other people's perceptions and experiences, fostering understanding and connection.ETGAR KERET (Cannes Film Festival Award-winning Director · Author of Fly Already · Suddenly a Knock on the Door · The Seven Good Years) shares insights from his upbringing and how his mother's storytelling shaped his perception of creativity and authenticity.ANTHONY JOSEPH (T.S. Eliot Prize-winning Poet, Novelist & Singer-songwriter · Author of Sonnets for Albert) discusses the fragmented documentation of Caribbean life and how his poetry attempts to piece together these fragments.CLAUDIA FORESTIERI (Emmy Award-winning Writer · Creator of HBOMax's Gordita Chronicles) talks about the crucial role of immigrants in building and revitalizing America, portraying them as "Born Again Americans."BRIGITTE MUNOZ-LIEBOWITZ (Showrunner Gordita Chronicles · One Day at a Time) highlights the inevitability of adversity in life and its role in fostering growth. She underscores the importance of a positive outlook in overcoming the challenges of immigration.JOHNJOE McFADDEN (Author of Life is Simple: How Occam's Razor Set Science Free and Shapes the Universe · Professor of Molecular Genetics at University of Surrey) explores the communicative power of art, detailing how complex ideas and feelings can be conveyed holistically.SHEHAN KARUNATILAKA (Booker Prize-winning Author of The Seven Moons of Maali Almeida) discusses his choice of writing in the second person to explore the spiritual dimension.CATHERINE CURTIN (Actress · Stranger Things · Orange Is the New Black · Homeland) reflects on creative freedom, experimental theater and her work in film and television.KATE MUETH (Founder/Artistic Director of the award-winning dance theater company The Neo-Political Cowgirls) emphasizes the importance of connecting stories to meaning and how her creative process prioritizes authenticity and personal fulfillment over industry expectations.To hear more from each guest, listen to their full interviews.Episode Websitewww.creativeprocess.info/podInstagram:@creativeprocesspodcast

How do the arts help us find purpose and meaning? What role do stories play in helping us preserve memories, connect us to each other, and answer life's big questions?MAX RICHTER(Award-winning Composer & Pianist · His album Sleep is the most streamed classical album of all time) reflects on the importance of creativity and how literature, music, and visual art offer windows into other people's perceptions and experiences, fostering understanding and connection.ETGAR KERET (Cannes Film Festival Award-winning Director · Author of Fly Already · Suddenly a Knock on the Door · The Seven Good Years) shares insights from his upbringing and how his mother's storytelling shaped his perception of creativity and authenticity.ANTHONY JOSEPH (T.S. Eliot Prize-winning Poet, Novelist & Singer-songwriter · Author of Sonnets for Albert) discusses the fragmented documentation of Caribbean life and how his poetry attempts to piece together these fragments.CLAUDIA FORESTIERI (Emmy Award-winning Writer · Creator of HBOMax's Gordita Chronicles) talks about the crucial role of immigrants in building and revitalizing America, portraying them as "Born Again Americans."BRIGITTE MUNOZ-LIEBOWITZ (Showrunner Gordita Chronicles · One Day at a Time) highlights the inevitability of adversity in life and its role in fostering growth. She underscores the importance of a positive outlook in overcoming the challenges of immigration.JOHNJOE McFADDEN (Author of Life is Simple: How Occam's Razor Set Science Free and Shapes the Universe · Professor of Molecular Genetics at University of Surrey) explores the communicative power of art, detailing how complex ideas and feelings can be conveyed holistically.SHEHAN KARUNATILAKA (Booker Prize-winning Author of The Seven Moons of Maali Almeida) discusses his choice of writing in the second person to explore the spiritual dimension.CATHERINE CURTIN (Actress · Stranger Things · Orange Is the New Black · Homeland) reflects on creative freedom, experimental theater and her work in film and television.KATE MUETH (Founder/Artistic Director of the award-winning dance theater company The Neo-Political Cowgirls) emphasizes the importance of connecting stories to meaning and how her creative process prioritizes authenticity and personal fulfillment over industry expectations.To hear more from each guest, listen to their full interviews.Episode Websitewww.creativeprocess.info/podInstagram:@creativeprocesspodcast

We love to hear from our listeners. Send us a message. Zandy Forbes, Ph.D. learned about business risk mitigation in the riskiest of business environments. She was a public markets healthcare investor on Wall Street for well more than a decade. Her hedge fund experience followed the Human Frontiers/Howard Hughes postdoctoral fellowship at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center that was preceded by an Oxford Ph.D. in Molecular Genetics. Since 2015, she's been drawing from her immersion in both the business and science disciplines as President & CEO at Meira GTx. On this episode of the Business of Biotech, Dr. Forbes and I go into deep analysis mode as we examine the risks she's taken in her current role, and how she applies her experiences – both good and bad – with handling other people's money to building a biotech company. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

References Guerra, DJ 2024. Biochemistry lectures de novo. Zevon, W. 1980. "Empty Handed Heart" https://open.spotify.com/track/2jqAdzGsLts2SPcDxNjqGJ?si=a3d0cf83804641c3 Manfred Mann [solo], Colin Pattenden, Peter Thomas .1976 "The Road to Babylon" https://open.spotify.com/track/7cUBAZwaFjPkdEkFMAGy7Y?si=210544d489544d29 Haydn, Michael. 1794. Excerpts from his Catholic Masses https://open.spotify.com/album/67v4gHJdnVWAn4erEtbuIc?si=3FHMYbRGQJaTHGbqYHHo8Q --- Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

Matters Microbial #68: Social Evolution in Viruses December 4, 2024 Today, Dr. Sam Díaz-Muñoz, Assistant Professor of Microbiology and Molecular Genetics, as well as a Faculty Member of the Genome Center at the University of California Davis, joins the #QualityQuorum to discuss how their group, and a growing community of researchers, investigates the social lives of viruses: the many ways that viruses interact and the ways that interactions shape infections and viral evolution.   Host: Mark O. Martin Guest: Sam Díaz-Muñoz Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode An article by Carl Zimmer on the social lives of viruses.' An overview of RNA viruses in general. An overview of cystoviruses. An overview of the use of cystoviruses in the study of evolution. A relevant article:  “Open Questions in the Social Lives of Viruses,” Leeks et al. 2023:  Another relevant article:  “Sociovirology: Conflict, Cooperation, and Communication among Viruses,” Díaz-Muñoz et al. 2017:  The website for the Social Lives of Viruses Meetings  An article from Jesse Bloom's lab showing the variation in single cell infection outcomes (Figure 4 is one of Dr. Díaz-Muñoz's favorites from any paper). The faculty website for Dr. Lin Chao, who was very influential in Dr. Díaz-Muñoz's background and promoted the study of evolution in microbes. The website for Dr. Paul Turner, who was very influential in Dr. Díaz-Muñoz's background and promoted the study of evolution in microbes. The website for Dr. Rich Lenski, who was very influential in Dr. Díaz-Muñoz's background  and promoted the study of evolution in microbes. A CDC article about “shift” versus “drift” in influenza.  A video by Dr. Díaz-Muñoz from 2020 about viruses. Dr. Díaz-Muñoz's faculty website. Dr. Díaz-Muñoz's laboratory group website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

This episode features a conversation between Dr. Timothy Cripe and Dr. Joseph Glorioso, who discuss an article published in Molecular Therapy Oncology by Dr. Glorioso and colleagues titled Oncolytic Herpes Simplex Viruses Designed for Targeted Treatment of EGFR-bearing Tumors. Join the editor-in-chief of Molecular Therapy, Dr. Roland Herzog, and ASGCT this January for the next installment of Molecular Therapy Presents: Clinical Gene and Cell Therapy. This transformative field has grown from promising experimental treatments to approved medicines for a wide range of genetic and/or acquired diseases. This virtual event is free for ASGCT members to attend and will highlight several in-depth invited reviews appearing in Molecular Therapy's Clinical Gene and Cell Therapy special issue. Attend the webinar and learn more about cutting-edge developments in the clinical space before the special issue is published in early 2025. Find Molecular Therapy Presents: Clinical Gene and Cell Therapy, and all upcoming ASGCT events at ASGCT.org/events.  In This Episode Timothy Cripe, MD, PhDEditor-in-Chief, Molecular Therapy Oncology and Professor and Chief of Hematology, Oncology, BMT at Nationwide Children's Hospital Dr. Joseph GloriosoProfessor, Department of Microbiology and Molecular Genetics and Department of Human Genetics at the University of Pittsburgh 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Dr. Lili Yang is a Professor of Microbiology, Immunology, and Molecular Genetics at the University of California, Los Angeles. Her research centers on deciphering the molecular mechanisms regulating anti-cancer immune responses, exploiting knowledge to develop novel immunotherapies for treating cancer, and translating these new cancer immunotherapies from bench to bedside. She talks about engineering off-the-shelf immunotherapies to fight cancer and generating CAR-NKT cells from hematopoietic stem and progenitor cells. She also discusses the role of serotonin and how SSRIs can affect cancer therapy efficacy.

Happy Monday, Fabulous Listener! And Happy Veteran's Day to all our listeners in the US. Thank you for your services! This evening, we have an amazing guest joining us today, the debut author, Ms. Jennifer Handler. We are going to be talking about her new book, KRISPR. This coming-of-age book will keep you hooked on the speculative science and the ongoing mystery behind it all. Jennifer Handler is a faculty member in The Department of Biology at Case Western Reserve University in Cleveland, Ohio. She holds a BS in Molecular Genetics and PhD in Genetics. She completed a post-doctoral fellowship in The Department of Neurosciences at The Cleveland Clinic and was a research associate in The Alzheimer's Research Laboratory at The CWRU School of Medicine. Much of the story of KRISPR is her story. Handler was born and raised in Cleveland but spent time as a young researcher at the prestigious Jackson Laboratory in Bar Harbor, Maine. Raising her family in the Midwest, she accompanied her teen-aged daughter to New York City where she participated in an international modeling competition, and later moved her into her dorm at a university in Midtown Manhattan. As a professor, Handler has a real sense of what it's like to be a college student in the 21st century. She also has the training and expertise to understand and make relatable technologies in genetics and neuroscience. Jennifer has experienced the heart-wrenching and devastating effects of Alzheimer's Disease as she witnessed her dad suffer from it for several years prior to his passing. To learn more about Ms. Jennifer and this book, check out her website at jennifer.handler.com. Thank you for joining us this evening. Always a pleasure bringing you new books from incredible authors. If you are enjoying the podcast and would like to stay in touch, subscribe. You don't want to miss a single episode. Happy Listening, DC

This episode features a conversation between Dr. Roland Herzog and Dr. Joseph Glorioso. On January 1, 2025, Dr. Glorioso will begin his 5-year term as the Editor-in-Chief of Molecular Therapy, marking the end of Dr. Herzog's successful tenure at the helm of the journal. Drs.Herzog and Glorioso engage in a wide-ranging conversation that touches on the history of Molecular Therapy, highlights from the gene and cell therapy field, and how Molecular Therapy will continue to grow and evolve under Dr. Glorioso's leadership. ASGCT is proud to present this episode of the Molecular Therapy Podcast in partnership with our upcoming Breakthroughs in Muscular Dystrophy conference on November 19th and 20th in Chicago, and virtually This event will provide an unparalleled opportunity to delve into the latest advancements in research on gene and cell therapies for muscular dystrophy. Learn more and register today at ASGCT.org/Breakthroughs. In This Episode: Dr. Roland HerzogEditor-in-Chief of Molecular Therapy and Professor of Pediatrics, Riley Children's Foundation Professor of Immunology, and Director of the Gene and Cell Therapy Program at Indiana University Dr. Joseph GloriosoProfessor, Department of Microbiology and Molecular Genetics and Department of Human Genetics at the University of Pittsburgh 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Dr. JoAnne Flynn is a Professor of Microbiology and Molecular Genetics at the University of Pittsburgh and Dr. Stephen Hedrick is Chancellor's Associates Chair VII Distinguished Professor Emeritus at the University of California, San Diego. They talk about the American Association of Immunologists' Immunology Explained campaign, which aims to explain the science of the immune system to the general public. They also discuss their efforts to educate legislators about the value of immunology research and promoting childhood vaccination.

Dr. Julia Olayanju is a scientist, educator and advocate for nutrition and health, best known for founding FoodNiche-ED, a platform that collaborates with schools and educators worldwide. Her work focuses on helping teachers promote science, health and nutrition education in K-12 classrooms. In our conversation, we discuss the significance of food science in schools, strategies to engage students on this topic, and the challenges and opportunities in equipping educators and students with a solid understanding of food science and health.  About Dr. Julia Olayanju Dr. Julia Olayanju is a scientist, educator and advocate for nutrition and health, best known for founding FoodNiche-ED, a platform that collaborates with schools and educators worldwide. Her work focuses on helping teachers promote science, health and nutrition education in K-12 classrooms. She earned her PhD in Microbiology and Molecular Genetics from Rutgers University, New Brunswick and an MPH from Harvard TH Chan School Of Public Health. Dr. Julia Olayanju on Social Media Twitter:  https://twitter.com/juliaolayanju  LinkedIn: https://www.linkedin.com/in/juliaolayanju/  Instagram: https://www.instagram.com/juliaolayanju/  Resources Listen to top experts on food and health: https://foodniche-ed.com/podcasts John Mikton on Social Media LinkedIn: https://www.linkedin.com/in/jmikton/ Twitter: https://twitter.com/jmikton Web: beyonddigital.org Dan Taylor on social media: LinkedIn: https://www.linkedin.com/in/appsevents  Twitter: https://twitter.com/appdkt  Web: www.appsevents.com Listen on: iTunes / Podbean / Stitcher / Spotify / YouTube Would you like to have a free 1 month trial of the new Google Workspace Plus (formerly G Suite Enterprise for Education)? Just fill out this form and we'll get you set up bit.ly/GSEFE-Trial

The fifth Season of the National Institute of Neurological Disorders and Stroke's Building Up the Nerve podcast, where we help you strengthen your science communication skills with tools and advice to use throughout your career. We know that navigating your career can be daunting, but we're here to help—it's our job!In the second episode of the season, we talk about Thriving in Team Science, focusing on how to build professional collaborations and guidelines to ensure success for all parties when working in team, especially across disciplines.Featuring Bosiljka Tasic, PhD, Director, Molecular Genetics, Allen Institute for Brain Science; Heidi Baumgartner, PhD, Research Scholar, Stanford University and Executive Director, ManyBabies; and Lingfei Wu, PhD, Assistant Professor, University of PittsburghResourcesArticles from Dr. Lingfei Wu:“Remote collaboration fuses fewer breakthrough ideas” (2023): https://pubmed.ncbi.nlm.nih.gov/38030778/ “Large teams develop and small teams disrupt science and technology” (2019): https://pubmed.ncbi.nlm.nih.gov/30760923/ Resources from ManyBabies: https://manybabies.org/resources/ ManyBabies Collaboration AgreementContributor Role Taxonomy (CRedIT): https://credit.niso.org/ Tenzing.club Protocols.ioTranscript available at http://ninds.buzzsprout.com/.

Subscribe to our channel: https://www.youtube.com/@optispan Check out Scott Carney's channel: https://www.youtube.com/@sgcarney Related episodes: The True Story of David Sinclair's Longevity Lie: https://www.youtube.com/watch?v=xQrXs7CxIjk DON'T Take Resveratrol Until You Watch This Video: https://youtu.be/MmIBdqsQYfw Scientists Debate How to Live Longer & Longevity Drugs: https://youtu.be/EebH_taOlAA An introduction to the study of RAPAMYCIN: https://youtu.be/czx_-DqnnrQ In this episode, Matt and Nick react to investigative journalist and author Scott Carney's video describing what he calls "David Sinclair's longevity lie" in the context of David's longevity-focused entrepreneurial ventures. Matt shares his professional history with David, including his early interactions with David in Leonard Guarente's lab at the Massachusetts Institute of Technology (MIT) and scientific differences that emerged after Matt and colleagues were unable to reproduce a key result from David's work pertaining to resveratrol. Their discussion touches on some of David's scientific claims about age reversal, the role of institutions such as Harvard University in regulating scientific integrity, the potential for future interventions in healthspan and longevity, and the importance of separating personal feelings from scientific evaluation. David, currently a professor in Harvard Medical School's Department of Genetics at the Paul F. Glenn Center for Biology of Aging Research, is a prominent geroscience researcher whose lab focuses on age-related epigenetic change, cellular reprograming, longevity drug discovery, mitochondrial fitness, reproductive aging, neurodegenerative disease, and the human secretome. He has received awards including the National Institutes of Health Nathan Shock Award, the Merck Prize, and the Australian Medical Research Medal, and was elected to TIME's 2014 “100 Most Influential People in the World" list. David conducted postdoctoral research at MIT and obtained a PhD in Molecular Genetics at the University of New South Wales. Producers: Tara Mei, Nicholas Arapis Video Editor: Jacob Keliikoa DISCLAIMER: The information provided on the Optispan podcast is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices. More places to find us: Twitter: https://twitter.com/optispanpodcast Twitter: https://twitter.com/optispan Twitter: https://twitter.com/mkaeberlein Linkedin: https://www.linkedin.com/company/optispan https://www.optispan.life/ Hi, I'm Matt Kaeberlein. I spent the first few decades of my career doing scientific research into the biology of aging, trying to understand the finer details of how humans age in order to facilitate translational interventions that promote healthspan and improve quality of life. Now I want to take some of that knowledge out of the lab and into the hands of people who can really use it.

Dr. Ludovic Vallier is the W3 Einstein Strategic Professor for Stem Cells in Regenerative Therapies at the Berlin Institute of Health and a Max Planck Fellow at the Max Planck Institute for Molecular Genetics. His lab uses stem cells to model embryonic development in vitro and to produce liver cells with an interest for cell therapy. He talks about modeling non-alcoholic fatty liver disease and his lab's pivot to SARS-CoV-2 research early in the pandemic. He also discusses how iPSCs could be used to regenerate the liver after injury.

Zandy Forbes, Founder, President, and CEO of MeiraGTx, joins host Rahul Chaturvedi in this compelling episode. Zandy shares her inspiring journey from academia, where she developed a deep interest in molecular biology and genetics, to her significant role in biotech investing, and eventually leading a groundbreaking gene therapy company. She elaborates on Meira's cutting-edge approach to genetic medicines, focusing on the development of innovative therapies for non-inherited diseases. Zandy discusses the unique challenges and opportunities that arise in the biotech sector, shedding light on the strategies Meira employs to navigate this complex landscape. Biography: Alexandria Forbes, Ph.D. is the President and CEO of MeiraGTx (NASDAQ: MGTX). MeiraGTx is a vertically integrated gene therapy company with core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. The company is developing innovative gene therapy products to cost effectively treat a range of serious medical disorders, with clinical programs currently in the eye, salivary gland and CNS. Prior to founding MeiraGTx, Dr. Forbes served as Senior Vice President of Commercial Operations at Kadmon Holdings, Inc., a biopharmaceutical company, from September 2013 to April 2015.Before joining the biotech industry, she spent 10 years as a healthcare investor at Sivik Global Partners (Argus Partners) and Meadowvale Partners. At Sivik, Dr. Forbes was responsible for investments in biotechnology, specialty pharmaceuticals and diagnostics public equities and was portfolio manager of the Sivik Global Life Science Fund, a long-biased public markets fund investing in biotechnology companies globally. During her time as a biotechnology investor, Dr. Forbes covered over 300 companies and gained expertise in biotechnology business strategies and clinical drug development as well as a wide range of disease areas. Particular areas of focus included HIV, HCV, diabetes, obesity, autoimmune disorders, cancer, Alzheimer's disease, kidney disease and liver disease. Before entering the hedge fund industry, Dr. Forbes was an academic scientist studying the regulation of stem cell identity and different aspects of embryogeneis. She was a Human Frontiers/Howard Hughes postdoctoral fellow at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center, where her research focused on cytoplasmic determinants and cell signaling pathways involved in the migration, establishment and maintenance of germ line stem cells in Drosophila melanogaster. Prior to this, Dr. Forbes was a research fellow at Duke University and at the Carnegie Institute at Johns Hopkins University where she studied the role of the hedgehog gene and its signaling pathway in the Drosophila embryo and adult. Dr. Forbes received her Ph.D. in Molecular Genetics from Oxford University, UK and attained a double first degree in Natural Sciences from Cambridge University, UK. Dr. Forbes serves on the Board of Directors of MeiraGTx, and as a Trustee and Director of the Selfridges Group Foundation, the European arm of the Weston Brain Institute, a charity supporting research into neurodegenerative diseases with the aim of speeding the time to the development of disease modifying treatments for these currently intractable diseases, particularly Alzheimer's.

Snezana Wood's story might be one that you think you know - however there's a lot more to her than you could possibly imagine. Today Osher speaks to this powerful mother of four who has a heck of a story to tell - it's so good that there's a whole book about it, which is incredible considering how busy a busy mum of four kids with a a degree in Molecular Genetics and Biotechnology must be. ‌ Her new book Untold: A story of love, motherhood, heartbreak and change is out now. ‌ For every episode ever and to get in touch head to oshergunsberg.com Hosted on Acast. See acast.com/privacy for more information.

Danielle Dick, PhD is the distinguished Commonwealth Professor of Psychology and Human and Molecular Genetics at Virgina Commonwealth University. She is an internationally recognized expert on genetic and environmental  influences on human behavior.  In this interview, we talk about her book The Child Code. In this book, she provides a interesting review on how genes influence behavior, spoiler alert-there isn't a gene for anxiety-it is more complicated. But more importantly from a parenting perspective, she provided a convenient way of thinking about temperament, what she called the 3 E's and quizes to help you figure out where you and your child are on this dimension. Importantly, she notes that we have to adjust our parenting style to match the temperament of your child. The Child Code is an extremely useful book for parents that is grounded in very solid science.   For more informaton about Dr Dick and access to her online resources for you to explore your child's genetic code. https://r.search.yahoo.com/_ylt=AwrhdUqZUoxmfFgfv7dXNyoA;_ylu=Y29sbwNiZjEEcG9zAzIEdnRpZAMEc2VjA3Ny/RV=2/RE=1721681818/RO=10/RU=https%3a%2f%2fwww.danielledick.com%2fabout/RK=2/RS=x9LSJGmG3cgi7kWLccRRgKZd2M0-

Johnjoe McFadden is Professor of Molecular Genetics at the University of Surrey, United Kingdom. He obtained his BSc in Biochemistry at the University of London, and his PhD at Imperial College London. He is an accomplished scientist and author. He has written several books, including "Quantum Evolution: Life in the Multiverse" (2000), "Life on the Edge: The Coming of Age of Quantum Biology" (2014), and his latest book "Life Is Simple: How Occam's Razor Set Science Free and Shapes the Universe" (2021). His research interests include systems biology, mycobacterial genetics, pathogenicity of tuberculosis, neisserial genetics, pathogenicity of meningococcal meningitis. However, along with Prof Jim Al-Khalili, he has become best-known for his contributions to the field of Quantum Biology. Prof McFadden also endorses a theory of consciousness wherein consciousness is an electromagnetic information field (known as CEMI Field Theory). TIMESTAMPS: (0:00) - Introduction (0:49) - What is Consciousness? (Quantum Biology) (6:37) - Consciousness as a an Electromagnetic Information Field (15:25) - Synchronization of neuronal activity (Constructive interference & awareness) (18:25) - What is CEMI Field Theory? (21:26) - Not all electromagnetic field theories of consciousness are "mystical" (physicalism vs materialism) (27:10) - NCCs vs Electromagnetic correlates of consciousness (31:30) - Michael Levin's work (35:49) - Consciousness EM Fields & Death (Conservation of Information) (40:25) - When do metaphysical claims break away from science? (Telepathy etc.) (47:05) - Synchronicity (conscious) vs asynchronicity (unconscious) (53:50) - Conscious AI (59:44) - When did our brain's EM Fields evolve "consciousness" and do other animals have it too? (1:04:50) - What does CEMI Field Theory say about Free Will? (1:08:23) - At what "age" (from embryo to adulthood) do our EM Fields synchronize? (1:11:50) - How can CEMI Field Theory make progress? (1:16:20) - Final thoughts 1:18:09 - Conclusion EPISODE LINKS: - Johnjoe's Website: https://johnjoemcfadden.co.uk - Work Website: https://www.surrey.ac.uk/people/johnjoe-mcfadden - Johnjoe's Publications: https://tinyurl.com/2s48mdnd - Johnjoe's Books: https://tinyurl.com/49kp3snf CONNECT: - Website: https://tevinnaidu.com - Podcast: https://podcasters.spotify.com/pod/show/drtevinnaidu - Twitter: https://twitter.com/drtevinnaidu - Facebook: https://www.facebook.com/drtevinnaidu - Instagram: https://www.instagram.com/drtevinnaidu - LinkedIn: https://www.linkedin.com/in/drtevinnaidu ============================= Disclaimer: The information provided on this channel is for educational purposes only. The content is shared in the spirit of open discourse and does not constitute, nor does it substitute, professional or medical advice. We do not accept any liability for any loss or damage incurred from you acting or not acting as a result of listening/watching any of our contents. You acknowledge that you use the information provided at your own risk. Listeners/viewers are advised to conduct their own research and consult with their own experts in the respective fields.

Chidozie Ojobor is a scientist-entrepreneur and is the cofounder and Chief Science Officer at Vitract, a microbiome company providing comprehensive and accessible gut testing to clinicians to improve the gut health of their clients/patients. Chidozie started his academic career in virus research, where he studied rotaviruses that cause gastroenteritis in children under the age of 5. Afterwards, he completed his PhD in Molecular Genetics at the University of Toronto where he was genetically engineering bacteriocins as novel therapeutic tools against bacterial pathogens. Chidozie developed interest in the microbiome during his doctoral research when he realized that the therapeutic entity he was developing had the potential to manipulate complex biological ecosystems such as the gut microbiome. After his PhD, he then cofounded Vitract, a microbiome company that provides insight into gut health based on the composition of gut bacteria in stool samples. Chidozie and his team are leveraging molecular sequencing techniques, AI and the robust body of scientific evidence associating the gut and overall health, to build comprehensive gut health solutions for Canadians and Americans.Get 25$ off your Vitract gut test with code FARMTOFUTURE at https://vitract.com/Scientific studies:Experimental mouse study on maternal glyphosate exposure and ASD:  https://pubmed.ncbi.nlm.nih.gov/32398374/ Epidemiological study on antibiotic use in infants and ASD:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164008/ C-section births and ASDHuman cohort study involving 5 million births https://pubmed.ncbi.nlm.nih.gov/28017932/ Experimental study in mice https://pubmed.ncbi.nlm.nih.gov/33903690/ Connect with Vitract:WebsiteInstagramLinkedInFacebookConnect with Jane Z. on Instagram at @farm.to.future

Optimizing your gut microbiome is arguably one of the most important things you can do for your health as it plays so many integral roles in almost every body system. This is why, in this episode of Biohacking Superhuman Performance, I chat with Chidozie Ojobor, Ph.D.  about the importance of the microbiome's influence on human health, particularly on the gut-brain connection and mental well-being.   He discusses the role of butyrate, leaky gut/brain, probiotics, and the importance of diet diversity in promoting a healthy microbiome. The conversation also covers the impact of modern lifestyle, antibiotics, and colon cleansing on gut health, and how to get accessible gut microbiome testing - in particular, the testing done by Vitract.    Chidozie Ojobor Ph.D. is a Molecular Biologist with over 12 years of experience in Medical Microbiology research, and the co-founder and Chief Science Officer of Vitract. In his early research years, he worked on human rotaviruses that cause severe gastroenteritis in children.   Afterward, he proceeded to earn his Ph.D. in Molecular Genetics from the University of Toronto, Canada. During his doctoral training, he developed through genetic engineering, novel therapeutic entities that target disease-causing bacteria such as the ones found in complex biological ecosystems as the gut microbiome. These tools he developed worked with high specificity and precision, making them the ideal candidates for targeted therapy. Dr. Ojobor's works in the fields he worked in have been well-cited by numerous scientists across the globe. Thank you to our sponsors for making this episode possible: CAROL Bike: Use code NAT for $100 off at www.carolbike.com Sensate: Use code NAT at www.getsensate.com/Nat  BiOptimizers: For Sleep Breakthrough use code bionat at checkout to save on your order and receive free gifts at www.bioptimizers.com/bionat    Find more from Chidozie Ojobor: Website: https://vitract.com/  Instagram: @vitractofficial Use Code NAT10 at vitract.com to save on a Vitract test   Find more from Nathalie: YouTube: https://www.youtube.com/channel/UCmholC48MqRC50UffIZOMOQ Join Nat's Membership Community: https://www.natniddam.com/bsp-community Sign up for Nats Newsletter: https://landing.mailerlite.com/webforms/landing/i7d5m0 Instagram: https://www.instagram.com/nathalieniddam/ Website: NatNiddam.com Facebook Group: https://www.facebook.com/groups/biohackingsuperhumanperformance   What We Discuss:  00:00 Introduction and Background 00:52 Advancements in Microbiome Research 04:39 The Significance of the Microbiome 05:09 The Gut-Brain Connection 06:22 Microbiome and Mental Health 08:11 The Role of Butyrate in Gut Health 09:06 Butyrate Supplementation 14:05 Leaky Gut and Leaky Brain 21:11 Foods that Promote Butyrate Production 23:06 Probiotics and Microbiome Diversity 29:23 The Role of Geography and Lifestyle in Gut Microbiome 30:03 The Importance of Gut Diversity for Health 31:35 Impact of Modern Lifestyle on Gut Diversity 32:30 Adaptation of the Gut Microbiome to the Environment 34:03 The Influence of Environmental Factors on the Gut Microbiome 35:14 The Complexity of Achieving the 'Perfect' Gut Microbiome 36:03 The Functional Level of the Gut Microbiome 37:19 The Impact of Antibiotics on the Gut Microbiome 39:10 The Resilience of the Gut Microbiome 40:33 The Use of Probiotics During Antibiotic Treatment 45:36 The Detrimental Effects of Prolonged Antibiotic Usage 48:19 The Link Between Food Poisoning and Gut Health 49:17 The Detrimental Effects of Colon Cleansing 50:45 The Controversy Surrounding Enemas and Colonics 53:19 The Impact of Chronic Stress and Antibiotic Overuse on the Microbiome 54:04 The Transition to Gut Microbiome Testing 55:28 The Need for Affordable and Comprehensive Gut Microbiome Tests 56:21 Understanding the Vytract Gut Microbiome Test 58:09 Transparency and Personalization in Gut Microbiome Testing 59:42 Short-Term Variability and Clinical Utility of Microbiome Testing 01:03:41 The Importance of Accepting Differences in Dietary Approaches 01:09:47 The Focus of Vytract's Gut Microbiome Test 01:11:30 Where to Find More Information and Order a Vitract Test Key Takeaways: Reduced gut diversity, often seen in individuals living in civilized nations, can have negative health implications. Antibiotics can disrupt the gut microbiome, and the use of probiotics during and after antibiotic treatment may help restore balance. Prolonged antibiotic usage can have long-term consequences for gut health, including increased risk of certain conditions. Colon cleansing and enemas may have detrimental effects on the gut microbiome and should be approached with caution. Chronic stress and antibiotic overuse can disrupt the microbiome. Gut microbiome testing provides valuable insights into gut health. Affordable and comprehensive tests are needed to improve access to microbiome testing. Short-term changes in the microbiome can have clinical utility.  

Evolution is sometimes described -- not precisely, but with some justification -- as being about the "survival of the fittest." But that idea doesn't work unless there is some way for one generation to pass down information about how best to survive. We now know that such information is passed down in a variety of ways: through our inherited genome, through epigenetic factors, and of course through cultural transmission. Chris Adami suggests that we update Dobzhansky's maxim "Nothing in biology makes sense except in the light of evolution" to "... except in the light of information." We talk about information theory as a subject in its own right, and how it helps us to understand organisms, evolution, and the origin of life.Blog post with transcript: https://www.preposterousuniverse.com/podcast/2024/02/19/266-christoph-adami-on-how-information-makes-sense-of-biology/Support Mindscape on Patreon.Christoph Adami received his Ph.D. in physics from Stony Brook University. He is currently professor of Microbiology and Molecular Genetics as well as Physics and Astronomy at Michigan State University. Among his awards are the NASA Exceptional Achievement Medal and the Lifetime Achievement Award from the International Society for Artificial Life. His new book is The Evolution of Biological Information: How Evolution Creates Complexity, from Viruses to Brains.Web siteMichigan State web pageGoogle Scholar publicationsWikipediaSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.